Synthesis of Retigabine Analogues for the Treatment of Tinnitus and Progress Towards a Concise Route to XJB-5-131 by Reed, Nicholas
face 
SYNTHESIS OF RETIGABINE ANALOGUES FOR THE TREATMENT OF TINNITUS 
AND PROGRESS TOWARDS A CONCISE ROUTE TO XJB-5-131 
 
 
 
 
 
 
 
 
By 
 
Nicholas Lawrence Reed 
 
B.Sc. in Chemistry, Purdue University, 2012 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
The Kenneth P. Dietrich School of Arts and Sciences in partial fulfillment 
 
of the requirements for the degree of 
 
Master of Science 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2014 
 
ii 
UNIVERSITY OF PITTSBURGH 
THE KENNETH P. DIETRICH SCHOOL OF ARTS & SCIENCES 
 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
Nicholas Lawrence Reed 
 
 
 
It was defended on 
 
 
November 18
th
 2014 
 
 
and approved by 
 
 
Alexander Deiters, Professor, Department of Chemistry 
 
 
Dennis P. Curran, Distinguished Service Professor of Chemistry and Bayer Professor, 
Department of Chemistry 
 
 
Thesis Director: Peter Wipf, Distinguished University Professor of Chemistry, Department of 
Chemistry 
 
 
iii 
Copyright © by Nicholas Lawrence Reed 
2014 
iv 
 
 The first part of this thesis describes the synthesis of retigabine analogues for the 
treatment of tinnitus.  Retigabine is a clinically proven anticonvulsant that modulates potassium 
ion channel activity and has been shown to stop the onset of tinnitus when administered shortly 
after exposure to extreme levels of sound.  Alteration of the fluorophenyl and carbamate 
functionalities present in the parent compound resulted in the synthesis of a small library of 
compounds with the goal of improving potency and selectivity for the Kv7.2/3 potassium ion 
channels.  In vivo and in vitro testing is underway to determine efficacy.     
The second part of this thesis describes efforts to develop and improved route to XJB-5-
131, a truncated Gramicidin S-derived peptide designed to control reactive oxygen species 
(ROS) production in mitochondria.  A new route to XJB-5-131 was explored utilizing a 
stereoselective α-alkenylation protocol and starting from vinyl boronic acids.    
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1.0  SYNTHESIS OF RETIGABINE ANALOGUES FOR THE TREATMENT OF 
TINNITUS 
1.1 INTRODUCTION 
 
1.1.1 Tinnitus 
 Tinnitus (Latin for “ringing”) is the perception of sound when no external sound1 is 
present.   In contrast to auditory hallucinations, which primarily manifest as voices or music, 
tinnitus involves buzzing, hissing, or ringing.  Sound generated from within the ear, termed 
objective tinnitus, results in noise that is audible to others.  Much more common, however, is 
subjective tinnitus in which sound is perceived only by the affected person and can range from 
barely audible to high-intensity.
1
  Its subjective nature makes tinnitus very difficult to diagnose 
and rate in terms of severity.  Due to its high prevalence around the world,
2
 especially among 
military veterans,
3
 efforts to identify and treat the underlying causes of tinnitus have intensified 
in recent years.  Initially thought to be a disorder affecting the cochlea, discouraging preclinical 
results with a variety of compounds that targeted the cochlea, combined with the development of 
an effective animal model of the disorder,
4
 have suggested that a central neurological mechanism 
is responsible for the induction and persistence of tinnitus.   
2 
  A particularly difficult aspect of treating tinnitus was its ambiguous molecular origin. 
Tinnitus appears to have a staggering numbers of factors associated with its induction and 
continuation.  Objective tinnitus tends to result from vascular abnormalities
5
 or spontaneous 
otoacoustic emissions
6
 while cochlear lesions (damage or reduced function of the cochlea) are 
the most obvious physical cause of subjective tinnitus.  Those with tinnitus typically have 
cochlear dead regions
7
 or outer hair cell damage.
8
  These observations only explain the induction 
of tinnitus, however, and not its persistence after the initial injury.   
Recently, it has been found that a homeostatic response affecting the neuronal activity of 
the auditory system could be responsible for compensatory auditory stimulation that leads to 
tinnitus.
9
  Building on previous work that identified the dorsal cochlear nucleus (DCN) as the 
critical component in the induction of tinnitus,
10
 Tzounopoulos and coworkers have described 
the pathogenic plasticity of Kv7.2/3 heteromeric potassium ion channels in the DCN as the 
primary mechanism of tinnitus induction.  Reduction of Kv7.2/3 potassium channel activity was 
shown to increase neuronal excitability through modulation of the resting membrane potential, 
the action potential threshold, the membrane potential spike that occurs after depolarization, and 
subthreshold excitability.
11
  In particular, reduced Kv7 ion channel activity prevents the 
termination of action potentials, leading to simulated auditory input (i.e. tinnitus).  
 In spite of intense research to identify and understand the underlying causes of tinnitus, 
there is currently no standard therapy or treatment.  Most treatments aim to alleviate symptoms 
or related abnormalities.  In addition to behavioral
12
 and sound therapy,
13
 hearing aids have been 
used to compensate for decreased input in the impaired frequency range.
14
  These therapies are 
limited to those with hearing loss and cannot be used in the high frequency range.  The use of 
3 
cochlear implants to restore input to the auditory system
15
 has also been shown to be effective in 
patients that exhibit bilateral sensorineural hearing loss.   
Pharmaceutical research has thus far resulted in no approved drugs in either the United 
States or Europe for the treatment of tinnitus.  The analgesic lidocaine has been shown to have 
transiently effective properties in the treatment of tinnitus when administered intravenously
16
 and 
for those patients with psychiatric disorders and tinnitus, carbamazepine has regularly been 
prescribed as a dual treatment in spite of studies showing a negligible benefit when compared 
with placebo (figure 1).
17
  With a stunning lack of options for those affected by tinnitus, 
examination of compounds that modulate Kv7 ion channel activity could lead to the development 
of an effective treatment. 
 
 
Figure 1. Structures of Lidocaine and Carbamazepine    
 
1.1.2 Kv7 Potassium Ion Channels 
Early work in the area of ion channels by Hodgkin and Huxley, who were able to derive a 
rigorous mathematical treatment of action potential initiation and propagation by likening the 
event to an electrical circuit, led to the 1963 Nobel Prize in Physiology and Medicine.
18
  Since 
that seminal work, significant efforts have been made to elucidate the mechanistic and structural 
features of specific types of ion channels
19
 (which resulted in the 2003 Nobel Prize in Chemistry) 
including voltage-gated potassium ion channels. Unlike sodium and calcium ion channels, which 
have pore-forming proteins primarily derived from one gene, the subunits of potassium ion 
4 
channels are encoded by separate genes and then assemble on various membranes to form ion 
channels.
20
  Subunits from different families of voltage-gated potassium ion channels can also 
combine to create biologically relevant ion channels,
21,22
 and, because of this heterogeneity, 
potassium ion channels serve a multitude of functions.  Voltage-gated potassium ion channels 
(Kv ion channels) have 12 subfamilies distinguished by their amino acid sequence (abbreviated 
with KvX.Y nomenclature, where X is the family and Y, the specific family member) and almost 
exclusively terminate action potentials in neurons.    
Structurally, Kv ion channels in vertebrates are comprised of four α-subunits that each 
contain six transmembrane helices (figure 2, S1-S6).
23
  Helices 1 to 3 arrange around the 
periphery of the ion channel and are joined by a conformationally flexible voltage sensing 
domain (S4) that responds to changes in the membrane potential.
24
  In particular, the S3 and S4 
domains form a hydrophobic helix-turn-helix structure that excludes several arginine residues 
(figure 2, indicated in green) and constitutes the voltage sensor paddle.  This structure, in light of 
contradictory electrochemical data,
25
 is thought to be conformationally flexible, allowing the 
voltage paddle to move freely around the outer edge of the ion channel.  The S5 and S6 domains 
form the lining of the pore domain through which potassium ions flow with the S6 domain 
forming the inner lining.  Opening and closing of the pore domain is controlled by a glycine-
gating hinge that was identified through analysis of crystal structures of open and closed 
bacterial potassium ion channels.
26
  The two domains maintain a roughly antiparallel alignment, 
indicating that the opening of the pore may occur by pulling the S5 helix away causing the S6 
helix to follow. 
 
5 
 
Figure 2.  Structure of KvAP Voltage-Gated Potassium Ion Channel α-Subunit showing Pauling-Corey-
Branson Helix (left) and Cartoon (right) Representations.
23
  Reproduced with permission from Ref. 23.
   
 
 The macrostructure of the Kv ion channel is comprised of four subunits arranged around a 
water-filled pore helix in a “teepee” structure that is in accordance with previously characterized 
bacterial ion channels and was confirmed by X-ray diffraction of crystallized KvAP ion channels 
from the extremophile aeropyrum pernix (figure 3).
23
  The high potassium ion selectivity is due 
to a signature sequence in the S6 domain that lines most of the pore helix, allowing for solvation 
of dehydrated potassium ions by the backbone carbonyl groups while excluding sodium or 
calcium ion on the basis of their size.
27
  The path through the pore itself is not a uniform 
structure, ranging from 3 Å at its narrowest to 15 Å at its widest and becomes a water-filled 
cavity half-way through.  Travel through the channels is controlled primarily through 
concentration gradients along the cell membrane and the channel itself which closes due to 
fluctuations in the membrane potential.  
    
6 
 
Figure 3.  Structure of the KvAP Potassium Ion Channel.  
23
 Reproduced with permission from Ref. 23. 
          
KCNQ genes encode for the five members of the Kv7 family of potassium channel 
subunits.  In the nervous system, Kv7.2 to Kv7.5 form the α-subunits of the low-threshold 
voltage-gated potassium channel
28
 and most channels are comprised of Kv7.2 and Kv7.3 
heteromeric
29
 or Kv7.2 homomeric subunits.
30
  These types of channels activate at subthreshold 
potentials and do not inactivate, providing a steady current that serves to stabilize the membrane 
potential and prevents burst-firing of neurons.  Because of their central role in modulating 
neuronal excitability, mutation of Kv7 ion channels has been associated with several disorders.  
Mutation of Kv7.1, for example, can lead to several different inherited arrhythmias including 
long QT syndrome.
31
  Thus, it should not be surprising that recent studies by Tzounopoulos and 
coworkers have implicated reduced Kv7.2/3 potassium ion channel activity in fusiform cells of 
the dorsal cochlear nucleus as a potential cause of tinnitus.
11
    Moreover, a recently approved 
drug for the treatment of partial-onset seizures, retigabine, is known to activate Kv7 ion channels. 
7 
  
1.1.3 Retigabine: Development and Drug Profile 
 Retigabine traces its origins to flupirtine, a structurally-related analgesic that derives its 
effectiveness through activation of Kv7 potassium ion channels.  This mechanism of action is 
now thought to be responsible for the variety of beneficial effects that have been observed for 
flupirtine including anticonvulsant,
32
 neuroprotective,
33
 and antiparkinsonian
34
 activity.  A large 
number of compounds were developed by Asta Medica (now Viatris) that resulted in the 
deazaflupirtine derivative D-20443 (retigabine, 1-1) which was extensively studied.
35
       
 
 
Figure 4.  Structures of Flupirtine and Retigabine (1-1)     
 
 Early studies showed retigabine to have a broad spectrum of activity in animals models of 
epilepsy.
36
  The mechanism of action was later shown to involve the opening of neuronal 
potassium ion channels, specifically Kv7.2-5 ion channels.
37
  A combination of electrochemical 
and site-directed mutagenesis experiments have determined that retigabine acts as a positive 
allosteric modulator of Kv7.2-5 with some selectivity for opening Kv7.2/3 heteromeric dimers 
over other subunit combinations.  This action controls neuronal excitability through 
hyperpolarization of the membrane, leading to reduced epileptic susceptibility.
38
  In addition, 
other ion channel and receptor families show no significant activity until high concentrations of 
the compound are reached,
37
 highlighting retigabine’s high selectivity.  The active site of the Kv7 
8 
ion channel has been deduced primarily on the basis of site-directed mutagenesis and 
electrochemical experiments
39
 which have identified crucial tryptophan, threonine, and leucine 
residues (figure 5).  The active site of Kv7.3 was then modeled with bound retigabine using a 
homology model derived from a Kv7.1 ion channel X-ray structure.  Given the location of the 
active site, retigabine likely does not alter the voltage sensing properties of the channel, instead 
stabilizing the open conformation of the ion channel through the S5 and S6 domains. 
 
 
Figure 5.  Proposed Binding Site of Retigabine: A) Three-Dimensional Model of Retigabine Docked to the 
Active Site of a Kv7.3 Domain and B) Crucial Amino Acid Residue Interactions.
39
  Adapted with 
permission from Ref. 39. 
 
 Based on favorable animal studies and preclinical studies, retigabine entered clinic trials 
in the early 2000s (after being licensed to several different pharmaceutical companies throughout 
the 1990s) and was found to reduce the frequency of seizures by 23 to 35% versus placebo with 
the most common side effects being dizziness, confusion, and slurred speech.
40
  Retigabine was 
approved by the FDA in 2010 under the name Potiga™, and has been consistently prescribed for 
partial-onset seizures.   
9 
 Retigabine and related analogues are available via several short synthetic routes.  
Reductive amination of 2-nitro-p-phenylenediamine and 4-fluorobenzaldehyde gives diamine 1-2 
in modest yield (scheme 1).  A three-step sequence beginning with catalytic hydrogenation, 
treatment with ethyl chloroformate to give 1-1, and addition of ethanolic HCl gives retigabine as 
dihydrochloride salt 1-3 in 62% yield.
41
  Simple purification of the final compound makes this 
method advantageous for gram-scale synthesis, but 1-3 is unstable and converts to cyclic urea 1-
4 when stored for long periods of time, even at -20 
o
C.
42
 
 
 
 Scheme 1.  Synthesis of Retigabine Dihydrochloride  
 
Selective carbamoylation of the diamine derived from 1-2 with ethyl chloroformate 
required slow addition of the chloroformate to minimize formation of bis-ethyl carbamate 
byproducts.  A second route utilizing the carbobenzyloxy (Cbz) protecting group was devised to 
avoid this problem (scheme 2).
43
  Intermediate 1-2 was protected with CbzCl and DIPEA and 
then carbamoylation using ethyl chloroformate gave 1-3 in good yield without the need for 
purification.  Subsequent cleavage of the Cbz protecting group and reduction of the nitro group 
using Pd/C and H2 gave retigabine (1-1) on gram-scale and in excellent overall yield. 
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 Scheme 2.  Synthesis of Retigabine Avoiding Polycarbamoylation 
 
 Several studies to determine the pharmacokinetic parameters of retigabine have been 
performed.
44
  Retigabine is rapidly absorbed and distributed with an oral bioavailability of 60% 
and a volume of distribution around 6.2 L/kg, reflecting its relatively high plasma protein 
binding (80%).
45
  Retigabine achieves a maximum concentration between 600-800 ng/mL in 1.5-
2 hours and has a half-life of approximately 8 to 10 hours.
46
  Patients typically receive doses of 
the compound two to three times daily which, when adjusted for plasma protein binding, results 
in a free concentration in plasma and the brain (due to its ability to easily cross the blood-brain 
barrier) near 1 μM.47 
 Retigabine is resistant to first-pass metabolism, being metabolized primarily via hepatic 
glucuronidation and acetylation at the N-2 and N-4 positions (figure 6), with the N2 position 
being preferred.
48
  UGT1A1 and UGT1A4 appear to be the primary glucuronosyltranferases that 
affect retigabine and a constant ratio between the decay of retigabine and its main metabolite has 
been found, suggesting the two compounds may be linked through enterohepatic circulation and 
a glucuronidation cycle.
48
  This is beneficial because glucuronidation via multiple UGT enzymes 
is a well-protected process, even in patients with a wide variety of hepatic diseases.  Due to slow 
UGT formation in the liver, however, this treatment is unlikely to be useful in very young 
children.  Retigabine also exhibits a moderate dependence on gender
45
 and race
49
 in terms of 
efficacy and metabolism, respectively.  Excretion of retigabine occurs renally, with roughly 84% 
11 
of the compound being recoverable as either the parent or a major metabolite when using 
14
C-
labelled compound.
50
   
 
 Figure 6.  Major Metabolites of Retigabine 
1.2 RESULTS AND DISCUSSION 
1.2.1 Analogue Design 
Structure-activity-relationship information for retigabine has been slow to appear
51
 and 
so far limited data has been reported for Kv7.2/3 ion channels.  Several patents have been 
published that report a variety of structures but are target multiple disease states and with limited 
evaluation of biological properties.
52
  Valeant pharmaceuticals reported several 4-(N-
azacycloalkyl)anilide derivatives that were found to be potent Kv7.2/3 activators with EC50 
values ranging from 1-500 nM (figure 7).
53
  The most important features were substitutions at 
both ortho positions around the carbamate, steric restriction of the benzyl amine as part of a 
tetrahydroisoquinoline ring, and replacement of the ethyl carbamate with a neo-pentyl amide.  
Several small groups were tolerated ortho to the carbamate (figure 7, R1) with methyl, methoxy, 
trifluoromethyl, and trifluoromethoxy substitution at both R1 and R2 leading to increased activity.  
12 
In addition, substitution of the tetrahydroisoquinoline ring was tolerated as well with fluorinated 
functional groups (F, CF3) in the 6 or 7 position being most potent (figure 7, R). 
 
 
Figure 7.  4-(N-Azacycloalkyl)anilide Derivatives for the Modulation of Kv7.2/3 Activity 
 
Icagen has also disclosed inhibitors that are structurally related to retigabine through 
elimination of two aniline nitrogen atoms from the core phenyl ring.
54
  Further replacement of 
the benzyl amine with an amide linkage resulted in compounds that had similar activity to 
retigabine (table 1).  Substituting the 2-position of the pyridine ring led to enhanced selectivity 
for Kv7.2/3 channels compared to other heteromeric and dimeric channels although these 
compounds were also active towards Kv7.1 indicating an altered mechanism of action.  Indeed, it 
was determined that these compounds do not bind to the S5 and S6 domain as retigabine does, 
indicating that the aryl diamine core is a necessary component of the structure. 
 
 
 
 
 
 
 
13 
Table 1.  N-(6-Substituted-pyridin-3-yl)-3,4-difluorobenzamide Derivatives as Kv7.2/3 Activators 
 
 
The groups of Nan and Gao have described the synthesis of bis-N-acylated retigabine 
derivatives that selectively inhibit Kv7.2 ion channels.
55
  Inhibition of Kv7.2 ion channels could 
be achieved at 100 nM by substituting various alkyl and allyl chains of medium length (n-propyl, 
1,1-disubstituted allyl) at N-4 and an ethyl carbamate at N-2.  Substitution at N-2 or N-4 alone 
leads to a loss of inhibitory activity for Kv7.2 but it is unknown whether the compounds activate 
the channels once more.  Kv7.2/3 potassium ion channels were not evaluated but it would be 
reasonable to suspect that heteromeric channels comprised of Kv7.2 subunits would also be 
inhibited.     
With regards to retigabine, several trends can be identified (figure 8) based on this 
literature precedent.  First, simultaneous substitution of both aniline nitrogen atoms is not 
tolerated.  Substitution ortho to the ethyl carbamate is tolerated well as long as both positions are 
substituted as is replacement of the ethyl carbamate with sterically-hindered amides.  The 4-
fluorophenyl ring can be substituted with a variety of functional groups but fluorinated 
functional groups tend to give greater potency compared to other heteroatoms.  The benzyl 
14 
amine can be conformationally constrained within a ring and might lead to greater potency by 
itself but substitution of the benzyl amine for an amide may result in an altered mechanism of 
action.  Replacement of the aryl diamine core with pyridine was also not tolerated.     
 
 
Figure 8.  Structure-Activity-Relationship of Retigabine 
 
The binding pocket of retigabine has been shown to contain a crucial tryptophan residue 
(figure 5, figure 9).
39
  Several leucine residues and a threonine residue also comprise the 
currently known binding site, although the exact shape and structure are unknown in the absence 
of crystallographic data.  The initial analogue design focused on altering two different sites on 
retigabine: first, the fluorophenyl functionality in zone 1 which targets the crucial tryptophan 
residue and second, the carbamate functionality in zone 2 (figure 10) which likely sits in a 
hydrophobic pocket in the active site but may also have a hydrogen-bonding interaction with 
T271.  The fluorophenyl functionality allows for the incorporation of several different aromatic 
and heteroaromatic structures with varying degrees of fluorination, in accord with the Wipf 
group’s keen interest in the selective incorporation of fluorine and fluorine-containing functional 
groups to natural products, peptides, and bioactive molecules.
56
  The second site of alteration 
15 
allows for the use of methodology previously utilized in the Wipf group
57
 to introduce several 
highly functionalized carbamates including those derived from the bis-oxetane sulfoxide, MMS-
350 (figure 12, 1-13),
58
 and 3-methyl-3-oxetanemethanol.
59
     
 
 
Figure 9.  2-Dimensional Representation of the Active Site of Retigabine (red = π-π stacking interaction, 
blue = hydrophobic interaction, magenta = hydrogen-bonding interaction) 
 
  
Figure 10.  Structure of Retigabine and Regions of Modification 
 
 Fluorine has been commonly employed as a bioisosteric replacement for the hydrogen 
atom due to its chemical inertness, ability to modulate pharmacokinetic parameters like pKa and 
lipophilicity, and increased metabolic stability relative to hydrogen.
60
  Higher order fluorinated 
functional groups like the trifluoromethyl- and pentafluorothio- (SF5) groups have also been used 
when a bulkier, more strongly electron-withdrawing functional group is wanted.  In particular, 
the SF5 group is rarely used in the synthesis of bioactive compounds despite its ability to greatly 
16 
increase lipophilicity and decrease metabolism across several atoms due to its difficulty of 
synthesis.
61
  Previous studies in the Wipf group have shown that selective incorporation of 
higher order fluorinated functional groups (CF3 and SF5) in bioactive molecules like Gramicidin 
S and Mefloquine can lead to improved peptide mimicry, potency, and selectivity.
56a, 56b
   
It was envisioned that trifluoromethyl- (1-5 and 1-6) and pentafluorothiophenyl 
analogues (1-7 and 1-8), as well as thiophene (1-11) and thiazole analogues (1-12) would allow 
us to probe the structure-activity relationship of retigabine.  A thorough analysis of the 
fluorinated benzene derivatives might reveal an electronic or steric requirement in the active site 
binding region of retigabine.  In addition, reports of SF5-containing compounds (1-5 and 1-6) are 
relatively scarce, especially in the context of bioactive analogues.  Thiophene is a typical 
benzene isostere and maintains roughly the same steric bulk and planar structure while being 
more electron-rich and polar, resulting in a lower logP value.  This could result in enhanced 
aqueous solubility.  The thiazole substitution has all of the above benefits as well as an additional 
nitrogen atom that could participate in hydrogen-bonding interactions with nearby donors, 
complementing the crucial π-π interaction of tryptophan-265 (figure 9) and leading to enhanced 
selectivity.  Additionally, alteration of the benzylic position (1-9 and 1-10) would allow for 
manipulation of the adjacent nitrogen atom by decreasing its basicity via inductive withdrawal or 
steric blocking.  The first pKa of retigabine as the free base has been calculated to be 13.1 at the 
N-2 position,
62
 a primary site of glucuronidation.  Decreasing the basicity of the secondary 
aniline could decrease clearance of the compound.   
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 Figure 11. Examples of Fluorinated and Heterocyclic Retigabine Analogues 
 
 Alteration of zone 2 (figure 10) had a more focused set of objectives.  Of particular 
interest to us were the isopropyl, MMS-350, and 3-methyloxetanemethanol derived carbamates.  
The isopropyl carbamate would function to probe the steric requirements around the core 
diamine.  MMS-350 (1-13) has gained attention as a method of combating radiation exposure
63
 
and as an additive to increase the aqueous solubility of small organic molecules (figure 12).
58
  
More recently, the Wipf group demonstrated its ability to enhance the solubility of bioactive 
molecules through covalent attachment.
57
  The covalently modified compounds showed 
increased solubility and membrane permeability.  Retigabine itself is very insoluble in aqueous 
solution (calculated to be 45 mg/L)
62
 with the hydrochloride salt being only sparingly soluble as 
well.
64
  Given the hydrochloride salt’s instability towards long-term storage,42 it was envisioned 
that a covalently modified MMS-350 derivative of retigabine (1-14) could impart aqueous 
solubility without negatively impacting stability (figure 12).  In the same vein, covalently linking 
3-oxetanemethanol (1-15) could improve aqueous solubility and has the potential for additional 
hydrogen bond interactions.    
 
18 
 
 Figure 12. Covalently modified MMS-350 and 3-Methyl-3-oxetanemethanol Retigabine Analogues 
1.2.2 Analogue Synthesis  
With the first set of analogues determined, initial synthetic efforts focused on 
synthesizing the fluorinated benzene derivatives of Retigabine.  Polycarbamoylation was 
anticipated to be a problem, therefore, protection of the secondary amine with CbzCl was seen as 
a preferable approach to access the desired compounds.  Condensation under Dean-Stark 
conditions in toluene and subsequent reduction of the intermediate imines with sodium 
borohydride furnished diamines 1-16 to 1-19 in good yield (scheme 3).  Severe streaking during 
chromatography even on Et3N deactivated SiO2 resulted in decreased isolated yields of 1-16 and 
necessitated purification of the intermediate imine before reduction with NaBH4.  This was 
accomplished by filtration through a small pad of SiO2 and removal of the residual solvent. 
 
 
 
Scheme 3.  Reductive Amination of 2-Nitro-p-phenylenediamine with Fluorinated Benzaldehydes  
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Protection of the secondary amine of 1-16 with CbzCl and DIPEA proceeds readily at 
room temperature (scheme 4).  Isolation of Cbz-protected amine 1-20 proved difficult due to 
streaking during chromatography on SiO2, thus crude 1-20 was treated with ethyl chloroformate 
and DIPEA in 1,4-dioxane to give 1-24.  Initial attempts to form the desired ethyl carbamate 
using a single equivalent of ethyl chloroformate did not proceed to completion even after heating 
and gave low yields of 1-24.  The reaction also appeared to stall after 48 hours with significant 
amounts of 1-20 remaining.  Several equivalents of ethyl chloroformate (2-5 equiv.) and DIPEA 
(2-5 equiv.), elevated temperatures, and extended reaction times were needed to achieve 
synthetically useful yields of 1-24.  Compounds 1-25, 1-26, and 1-27 were synthesized in a 
similar sequence.  The low reactivity of the aniline was attributed to the presence of an ortho-
nitro group as well as the electron deficient nature of the core aromatic ring overall.  In addition, 
the 3-substituted phenyl derivatives (1-25 and 1-27) gave products that could not be purified by 
chromatography on SiO2 due to inseparable byproducts resulting from polycarbamoylation. 
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 Scheme 4. Protection and Carbamoylation of Reductive Amination Products  
 
All attempts to increase the effectiveness of the reaction using N-methyl amines (DMAP) 
or NaH as the base failed to give increased yields.  By 
1
H NMR analysis, the primary byproduct 
appeared to be polycarbamoylated compounds resulting from unreacted starting material in the 
protection step (several quartet-triplet pairs indicating ethyl groups were present).  
Hydrogenolysis of the Cbz group and reduction of the nitro group were accomplished using Pd/C 
and H2 to give 1-5 to 1-8 in good yields (scheme 5).  The 3-substituted phenyl derivatives gave 
decreased yields over the 3 step sequence due to low conversion in the protection step.  This 
resulted in more residual starting material (1-17 or 1-19) that could give polycarbamoylated side 
products when treated with ethyl chloroformate.     
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 Scheme 5.  Reduction and Cleavage of Cbz Protecting Group Using Catalytic Hydrogenation 
 
 Compound 1-10 could be envisioned to arise from addition of trifluoromethyl anion 
(derived from the Ruppert-Prakash reagent and a fluoride source) into an electron deficient imine 
like 1-28 (itself obtained by condensation of 4-pentafluorothiobenzaldehyde and 2-nitro-p-
phenylenediamine in 64% yield).  These attempts were met with failure.  Conditions known to 
add trifluoromethyl anion into electrophilic imines under acidic conditions
65
 gave only recovered 
starting material or complex mixtures by LC-MS and 
1
H NMR (scheme 6).  In light of these 
difficulties, the previously described reductive amination strategy was used to access compound 
1-29. 
 
 
 Scheme 6.  Attempted Nucleophilic Trifluoromethylation of Pentafluorosulfanylimine 1-28 
  
Reductive amination of 2,2,2-trifluoroacetophenone and 2-nitro-p-phenylenediamine 
under Dean-Stark conditions in toluene lead to poor conversion and isolated yields (ca. 12%) of 
1-29 (Scheme 7) with significant quantities of residual starting material even after extended 
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reaction times.  Comparable yields were obtained utilizing a procedure promoted by 
AlMe3/BH3·SMe2
66
 and no product was observed using molecular sieves at room temperature.  
Attempted protection of the secondary aromatic amine of 1-29 resulted in the incorrect 
regioisomer 1-30 in 75% yield.  This serendipitous result indicated that the trifluoromethyl group 
inductively deactivated the adjacent amine enough to do away with the use of a protecting group.    
 
 
 Scheme 7.  Reductive Amination and Protection Affording Regioisomer 1-30  
 
Thus, treatment of 1-29 with ethyl chloroformate at room temperature for 24 h and then at 50 
o
C 
for a further 24 h gave ethyl carbamate 1-31 in 73% yield (scheme 8).  Subsequent reduction 
with Pd/C and H2 proceeded in excellent yield to give 1-10. 
 
 
 Scheme 8.  Carbamoylation and Catalytic Hydrogenation of 1-29 
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 Deuterated analogue 1-9 required the synthesis of deuterated benzaldehyde 1-33, which 
commenced with formation of Weinreb amide 1-32
67 
in quantitative yield (Scheme 9).  
Reduction using LiAlD4 gave 1-33 which was subjected as a crude mixture to the previously 
described reductive amination conditions using NaBD4 to give 1-34 in a moderate 42% yield 
over 2 steps.  Attempts to isolate 1-33 proved difficult due to volatility.   
 
 
 Scheme 9.  Synthesis of Deuterated Reductive Amination Product 1-34 
 
Protection and carbamoylation proceeded in comparable yield (56%) to previously 
prepared analogues to give 1-36.  Reduction of the nitro group and cleavage of the Cbz 
protecting group using Pd/C and H2 gave the desired deuterated analogue 1-9 in 75% yield 
(scheme 10). 
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 Scheme 10.  Synthesis of Deuterium-Labelled Retigabine 
 
 The final compounds to be made with alterations in zone 1 incorporated heteroaromatic 
structures.  Reductive amination using the previously described conditions (PTSA, toluene, 
reflux) gave impure material in diminished yield due to unknown side reactions.  Purification 
was also complicated by the increased polarity of the heteroaromatic rings.  A new reductive 
amination procedure employing molecular sieves was adapted from a previously reported 
procedure.
68
  Use of molecular sieves and PTSA as a catalyst at room temperature allowed for 
the isolation of diamines 1-37 and 1-39 in 71% and 61% yield, respectively (scheme 11) without 
the need for column chromatography.  Interestingly, 1-37 seemed to form a 1:1 mixture with the 
intermediate imine during reduction with NaBH4 and required prolonged reaction times to 
proceed to completion.  Protection and treatment with ethyl chloroformate gave ethyl carbamates 
1-38 and 1-40 in good yield over 2 steps.  
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 Scheme 11.  Initial Attempts towards Heterocyclic Analogues of Retigabine 
 
Reduction of the nitro group of 1-40 or its thiophene counterpart was easily accomplished 
using Pd/C and H2, but removal of the Cbz group and isolation of the desired compounds could 
not be realized under a variety of conditions including high pressure and temperature catalytic 
hydrogenation, transfer hydrogenation, and strongly acidic conditions.  Strongly acidic 
conditions using HBr in AcOH resulted in intramolecular condensation leading to a cyclic urea 
that coeluted by TLC with the desired product.  Reversing the reaction order (cleavage of the 
Cbz group followed by reduction of the nitro group with Pd/C) did not afford desired product 1-
12 in pure form or acceptable yields either. 
 A revised route was obviously needed.  Eschewing the use of a protecting group, 
reduction of the nitro group of 1-37 or 1-39 leading to an aryl triamine followed by treatment 
with an attenuated ethyl chloroformate equivalent could lead to the desired compounds without 
polycarbamoylation.  Previous studies in the Wipf group involving MMS-350 had utilized mixed 
phthalimidyl carbonates and observed that they react readily with aromatic amines to give 
covalently linked MMS-350 derived carbamates.
57
  Similar reagents have also been shown to be 
effective carbamoylating agents.
69
  Reduction of the nitro group of 1-37 and 1-39 using Pd/C and 
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H2 and subsequent reaction with mixed phthalidimidyl carbonate 1-41 and Et3N in CH2Cl2 gave 
the desired heterocyclic analogues (1-11 and 1-12) in good yield over 2 steps (scheme 12).  This 
sequence has several advantages including the use of air and moisture stable carbamoylating 
reagents, shorter overall step count, and comparable overall yields.       
 
 
 Scheme 12.  Synthesis of Heterocyclic Analogues of Retigabine 
 
 The analogues with alterations in zone 2 of retigabine were surprisingly difficult to 
access.  Initial attempts to prepare the desired compounds involved the previously described 
reductive amination-protection-carbamoylation sequence to yield 1-43.  Attempts to prepare 
functionalized carbamate equivalents using carbonyl diimidazole-derived reagents
70
 led only to 
recovered starting material and formation of the corresponding isocyanate of 1-42 with 
phosgene
71
 and addition of the corresponding alcohols led to mixtures of products by LC-MS 
that were inseparable by TLC.  The only compound successfully prepared via this route was 
isopropyl carbamate analogue 1-44 due to the ready availability of isopropyl chloroformate.  
27 
Reductive amination gave diamine 1-2 in 62% yield which was then protected and treated with 
isopropyl chloroformate, affording only 39% of the desired product over 2 steps (scheme 13).  
Catalytic hydrogenation of 1-43 using Pd/C and H2 gave 1-44 in good yield (74%). 
 
 
 Scheme 13.  Synthesis of Isopropyl Carbamate Analogue 1-44 
 
The synthesis of 1-44 drew our attention to a key limitation of our strategy; acid-sensitive 
functionalities would likely not survive the formation of the chloroformate using traditional 
methods
72
 and yields would likely be low.  In particular, MMS-350 had previously shown acid 
instability. Thus, taking lessons learned from the heterocyclic analogues of retigabine and the 
work done in the Wipf group,
57
 mixed phthalidimidyl carbonates appeared to be a superior 
method to access these compounds.  1-46 and 1-47 could be prepared from diphthalidimidyl 
carbonate and enabled controlled carbamoylation without any evidence of polycarbamoylation 
(scheme 14).  Thus, catalytic hydrogenation of 1-2 yielded triamine 1-45 which was then treated 
with a mixed carbonate (1-46 or 1-47) and Et3N.  Purification of compound 1-15 was 
complicated by closely eluting impurities but could be obtained in 29% yield over 2 steps.  The 
MMS-350 derived compound 1-14 was obtained in better, albeit still modest, 39% yield.   
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 Scheme 14.  Synthesis of MMS-350 and 3-Methyl-3-Oxetanemethanol Modified Analogues 
 
1.3 CONCLUSIONS 
A small collection of retigabine analogues was synthesized exploring various alterations 
which included fluorinated phenyl, heteroaromatic, benzylic, and carbamate alterations to the 
parent compound.  Initially, several analogues were prepared utilizing a protecting group 
sequence that exhibited severe limitations.  A new, shorter route was developed involving 
reductive amination, reduction of the nitro group, and treatment with mixed phthalidimidyl 
carbonates to deliver the final compounds in good overall yields.  Overall, 11 compounds were 
synthesized and are awaiting in vitro and in vivo biological evaluation.   
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2.0  PROGRESS TOWARDS A CONCISE ROUTE TO XJB-5-131 
2.1 INTRODUCTION 
2.1.1 Mitochondrial Production of Reactive Oxygen Species and XJB-5-131 
The “free radical theory of aging” proposed by Harman in 1956 hypothesized that free 
radicals, most likely produced within an organism, lead to the detrimental effects of aging.
73
  
Since Harman’s seminal publication, reactive oxygen species (ROS) have been associated with 
the a variety of detrimental cellular effects and disease states
74
 including Alzheimer’s disease, 
Parkinson’s disease, stroke, and cancer.75  The theory has also been expanded to include 
oxidizing oxygen species like peroxides, singlet oxygen, and ozone.  With the vast majority of 
ROS being produced in the mitochondria during the oxidative phosphorylation (OxPhos) process 
(Figure 13),
74
 it comes as no surprise that most efforts to control ROS production target the 
mitochondria.
76
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Figure 13.  Production of Reactive Oxygen Species in the Electron Transport Chain.
77
  Adapted by 
permission from Ref 77. 
 
Because antioxidants have proven ineffective at combating oxidative damage in animal 
models due to localization problems,
78
 targeting of the inner mitochondrial membrane by 
external ROS scavengers has been achieved in a variety of ways.  Taking advantage of several 
distinct features of the inner mitochondrial membrane,
79
 most targeting methods can be 
described as either non-peptidic or peptidic in nature (Figure 14).  Non-petidic methods 
(lipophilic cations, sulfonyl urea compounds, anthracyclines, etc.) typically involve modulation 
of the mitochondrial membrane potential (either inadvertently or by design) or damage of 
mitochondrial membrane proteins.
76
  Each of these processes can be useful in targeting 
mitochondria but they have significant side effects that limit their effectiveness, such as 
destabilization of the mitochondrial membrane which can lead to eventual cell death.  
Peptide mimics have also been shown to localize effectively in mitochondria.  The Szeto-
Schiller (SS) peptides utilize a 2’,6’-dimethyltyrosine unit that acts as the ROS scavenging 
payload with the rest of the peptide consisting of alternating basic and aromatic residues serving 
to localize the compound in the inner mitochondrial membrane,
80
 with enhancements of up to 
600-fold being achieved.  Wipf and Xiao synthesized a variety of truncated Gramicidin S-
31 
derived ROS scavengers that localize in the inner mitochondrial membrane
81
 and utilize a stable 
nitroxide radical, 4-amino-TEMPO, as the ROS scavenging moiety.   
 
 
Figure 14.  Mitochondrial Targeting Strategies.
76
  Adapted by permission from Ref. 76.    
 
XJB-5-131 (figure 16) was the result of extensive experimentation with Gramicidin S 
(figure 15), a mitochondrial membrane-active decapeptide that contains 2 type II’ β-turns, an 
unnatural D-phenylalanine residue, and an ornithine residue.  Gramicidin S was initially used as 
a topical antibiotic in World War II due to its wide spectrum antibiotic and antifungal properties.  
Crystallographic structural confirmation was not obtained until 1978 when Dodson and 
coworkers solved the crystal structure of a Gramicidin S-urea complex to 1 Å resolution,
82
 
indicating a slightly distorted conformation from that proposed by Hodgkin and Schmidt.
83
  The 
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crystal structure confirmed the presence of two type II’ β-turns as well four internal hydrogen 
bonds that serve to stabilize the dimeric structure. 
 
 
Figure 15.  Structure of Gramicidin S   
  
Utilizing a truncated version of 2-1 that incorporates an ROS scavenging moiety, directed 
delivery could be achieved with a compound that would be more amenable to synthesis and 
diversification.  Thus, Xiao and Wipf synthesized a variety of truncated Gramicidin S 
derivatives.  XJB-5-131 (Figure 16, 2-2) was found to localize in mitochondria based on analysis 
of electron-spin resonance spectra.
81
  As a consequence of its localization properties, 2-2 has 
shown promise in animal models of radiation sickness,
63
 neurodegeneration,
84
 and lethal 
hemorrhagic shock.
85
  Attempts to further simplify the structure of XJB-5-131 led to the 
development of JP4-039
86
 (Figure 16) which has shown to be particularly effective in combating 
radiation exposure.
87
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Figure 16.  Structures of XJB-5-131 and JP4-039 
 
The initial synthesis of XJB-5-131 required nearly 20 steps and the separation of a 1:1 
mixture of diastereomers.  While delivering the final compound in good overall yield and 
allowing for the preparation of enough material for initial biological assays, the length of this 
synthetic sequence would make gram-scale quantities of the target compound difficult to access.  
A shortened route was developed
88
 starting from commercially available homopropargyl alcohol 
that utilized zirconium transmetallation methodology previously developed in the Wipf group 
(scheme 15).
89
  Hydrozirconation of homopropargyl alcohol with Schwartz’s reagent, 
transmetalation from Zr to Al, and then addition into sulfinimine 2-3 gave 2-4 with high 
diastereoselectivity.  Interestingly, this process was hypothesized to proceed through a 4-
membered chelate transition state.  Several protecting group manipulations gave alcohol 2-5 
which was subsequently oxidized and the Evan’s auxiliary appended to give 2-6.  Alkylation 
with benzyl bromide and cleavage of the chiral auxiliary with LiOH and H2O2 gave 2-7 in 
excellent overall yield.   
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Scheme 15. Synthesis of Protected Amino Acid 2-7 
 
With the most difficult part of the molecule synthesized, peptide coupling of 2-7 with H-
Pro-Val-Orn(Cbz)-OMe using EDC and HOBt gave 2-8 in excellent yield and hydrolysis of the 
pendant methyl ester and subsequent peptide coupling with 4-amino-TEMPO (4-AT) affords 2-2 
(scheme 16).  Overall, 12 steps (LLS) deliver the desired compound in 34% yield, and this route 
has been used to synthesize gram-scale quantities of the target compound.  In spite of its high 
efficiency, six steps in this route serve to manipulate either protecting groups or chiral auxiliaries 
and represent nearly half of the actual synthetic sequence.  In addition, stoichiometric quantities 
of each chiral auxiliary are needed, representing a significant dollar cost if large quantities of 
material are needed.  Thus, we began looking at new disconnections towards amino acid 2-7 in 
an attempt to streamline the synthesis.  In particular, recent advances in the stereoselective 
synthesis of α-alkenylated carbonyl compounds seemed like a good starting point in our 
endeavors. 
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Scheme 16. Late-Stage Peptide Couplings to Synthesize XJB-5-131 
2.1.2 Stereoselective Alkenylation of Aldehydes: Difficulties and Approaches 
The stereoselective α-alkenylation of carbonyl compounds has been a long sought-after 
transformation.  It is often not possible to employ traditional procedures involving enolate 
chemistry for a variety of reasons (figure 17).  First, even if satisfactory enantioenrichment 
occurs, the resulting products would be more acidic than the starting materials.  Quantitative 
enolate formation is an option but requires carefully controlled reaction conditions and the use of 
dangerously reactive chemicals.  Second, olefin isomerization to give α,β-unsaturated carbonyl 
compounds is a potential problem, especially when transition metal complexes are used.  The 
olefin reaction partners are usually not electrophilic enough to directly participate in these types 
of transformations either and require an electron-withdrawing functionality (α,β-unsaturated 
ketone, ester, nitrile, nitro, etc.) and a terminal leaving group (vinyl halide, tosylate, etc.) to 
achieve the same reactivity patterns as alkyl halides or sulfonates.   
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Figure 17. Difficulties and Desired Transformation Associated with α-Alkenylation of Carbonyl 
Compounds 
 
 The α-alkenylation of carbonyl compounds is a direct extension of earlier work to 
develop α-arylation procedures.  Several groups, particularly those of Buchwald and Hartwig, 
have developed suitable procedures
90
 that utilize basic conditions to enolize various types of 
carbonyl compounds.  The resulting products were racemic and non-enolizable, so racemization 
was not a concern.  In order to allow for a wider variety of substrates, Hartwig and coworkers 
have also developed milder procedures utilizing preformed silyl enol ethers and Lewis acid 
catalysts which have been found to avoid epimerization of the resulting stereocenters, react more 
quickly, and give higher selectivity.
91
  The scope with regards to the silyl enol ether was broad 
allowing even sterically hindered enolates to be successfully arylated with high selectivity in 
synthetically useful yields.  Particularly useful was the use of chiral oxazolidinones allowing 
highly diastereoselective couplings of aryl bromides (scheme 17). 
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 Scheme 17.  Diastereoselective α-Arylation of Trimethylsilyl Enolates Using the Evans’ Auxiliary  
 
In recent years, catalytic and stereoselective methods for generating α-alkenyl carbonyl 
compounds have emerged.  Beginning with stereoselective α-arylation procedures,92 α-vinylation 
has gained popularity as more powerful methods of catalysis are developed.  Buchwald and 
coworkers have demonstrated that palladium can competently couple vinyl bromides and ketone 
enolates (Scheme 18).
93
  Enantiomeric excesses of up to 94% were realized by using axially 
chiral phosphine ligands and catalytic Pd2(dba)3, but this achievement was tempered by the fact 
that the reaction is highly substrate dependent.  Enantiomeric excesses were greatly diminished 
when cis olefins or cyclohexanones were used.  This methodology also requires the use of a 
blocking group in the α’-position due to the strongly basic reaction conditions.     
 
 
 Scheme 18. Enantioselective Palladium-Catalyzed Vinylation of Ketone Enolates 
 
 In 2009, the same group was able to show that oxindoles were suitable substrates for α-
arylation and α-vinylation when axially-chiral P-stereogenic ligands were used in combination 
with a palladium precatalyst.
92b
  All examples of arylation proceed in good to excellent yield 
with excellent enantioselectivity but interestingly, alkenylation using trans- and cis-1-bromo-1-
38 
propene gave highly divergent selectivity (Table 2, entries 1 and 2) though no explanation was 
put forth to explain the discrepancy.  2-Bromopropene was a competent substrate (Table 2, entry 
3) giving good yields and excellent selectivity.  Likewise, a mixture of cis/trans isomers of β-
bromostyrene was subjected to vinylation conditions and a mixture of products was obtained 
with the cis-isomer showing significantly higher enantioinduction than the trans-isomer (Table 2, 
entry 4). 
 
Table 2. Enantioselective α-Vinylation of Oxindoles with 1-Bromo-1-propene and β-Bromostyrene 
 
   
 The Fu group has investigated the Hiyama coupling of racemic α-bromoesters with aryl 
and vinyl silanes using a chiral nickel-diamine catalyst system (Table 3).
94
  The reaction 
proceeded in moderate yield with high enantioselectivity.  This process likely proceeds through 
the standard oxidative insertion-transmetallation-reductive elimination sequence common to 
palladium and nickel catalytic cycles with isomerization possible through a η3 π-complex.  
Alkenyl (Table 3, entries 1 and 3) and styrenyl (Table 3, entry 2) silanes were able to deliver the 
corresponding alkenylation products in good yield and high enantioselectivity. 
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Table 3. Asymmetric Hiyama Coupling of α-Bromo Esters and Vinyl Silanes 
 
  
 The same group was later able to show that alkenylzirconium compounds were 
competent substrates in this transformation.
95
  Reaction with α-bromo ketones using a chiral 
nickel-bisoxazoline system gave the desired α-alkenylation products with good to excellent 
enantioinduction (80-95 %ee) and good yields (Scheme 19).  The most commonly used 
substrates were aryl ketones, though some alkyl and benzyl ketones were also used and gave 
comparable yields and selectivity.  This type of transformation complements a broader class of 
similar transition-metal catalyzed reactions that have been developed with a variety of 
organometallic reaction partners (boron, zinc, magnesium, silicon, tin, and indium compounds).
96
  
This process has limited functional group compatibility, however, due to the hydrozirconation 
reaction used to generate the requisite substrates.   
 
 
Scheme 19. Enantioselective Cross-Coupling of Racemic α-Bromo Ketones with Alkenyl Zirconium 
Compounds   
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 Organocatalytic methods for α-alkenylation have recently begun to surface as alternatives 
to traditional transition-metal mediated processes that typically suffer from limited substrate 
scope and modest functional group compatibility.  These types of processes have several 
advantages when compared to transition metal mediated processes, including mild reaction 
conditions and reduced likelihood of product racemization.  The most direct method of 
enantioselective α-alkenylation was developed by Jørgensen and coworkers who utilized cyclic 
β-ketoesters in a conjugate addition-elimination procedure under phase-transfer conditions 
mediated by cinchona alkaloid-derived catalysts (Scheme 20).
97
  The reaction gave good to 
excellent yields with excellent enantioselectivity.  The mechanism of this transformation is 
thought to involve enolization of the β-ketoester forming a chiral ion-pair, which can then 
undergo conjugate addition with the β-chloroenone to generate a set of diastereomeric enolates.  
Expulsion of the halide results in a stereospecific regeneration of the alkene to generate the 
desired α-alkenylation product.  In order to expand the types of substrates that can be used, 
however, a more general approach had to be developed that does not rely on premade olefins and 
the creation of non-enolizable stereocenters. 
   
 
 Scheme 20. α-Alkenylation of β-Ketoesters using Cinchona Alkaloid-Derived Organocatalysts 
 
 More recently, the MacMillan group has reported several different methods of preparing 
α-alkenylation products using aldehydes as the carbonyl component.  Due to the mild reaction 
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conditions and the nature of the organocatalyst, racemization of the resulting α-alkenyl aldehydes 
is disfavored.  Furthermore, the versatility of the resulting aldehydes (reduction to alcohols, 
oxidation to carboxylic acids, reduction to alkyl chains, Wittig reaction, addition of nucleophiles, 
reductive amination, homologation to the terminal alkyne, etc.) makes this strategy attractive for 
complex molecule synthesis.
98
 
 Early work in this area utilized alkenyl trifluoroborate salts and aldehydes under organo-
SOMO catalysis conditions (Scheme 21).
99
  Initial condensation of imidazolidinone catalyst 2-9 
with an aldehyde gives an enamine which can be oxidized by CAN to give radical cation 2-10.  
Subsequent radical addition to the alkenyl trifluoroborate reaction partner gives radical cation 2-
11 which can then be oxidized further to dication 2-12.  A trans-selective Peterson-type 
elimination leads to enantioenriched α-alkenylation product 2-13 which can be hydrolyzed to 
give 2-14 and regenerate catalyst 2-9.  This procedure was used with a variety of aldehydes 
(alkyl, alkene-containing, cycloalkanes, benzyl, protected alcohols, and protected amines) and 
alkenyl trifluoroborate salts (substituted styrenes and alkyl) giving good yields and excellent 
enantioselectivity in all cases.  This methodology was applied to the synthesis of a challenging 
all-carbon quaternary center (Scheme 22).  The initial α-alkenylation product was treated with 
vinyl Grignard reagent to give a 1:1 diastereomeric mixture of 2-15 which could be subjected to 
anionic Oxy-Cope conditions to give aldehyde 2-16 with excellent enantio- and 
diasteroselectivity. 
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Scheme 21.  Mechanism of Organo-SOMO Catalysis Using Chiral Imidazolidinones 
 
 
Scheme 22.  Anionic Oxy-Cope Strategy to All-Carbon Quaternary Centers 
  
Synergistic catalysis takes advantage of two separate catalytic cycles that can intersect 
each other with intermediates that react to give the desired product and regenerate one or both of 
the catalysts in the process.  This type of transformation has become prominent in recent years.
98, 
100
  Copper catalysis has been used in previous procedures that couple aryl groups with various 
nucleophiles.  Electrophilic organocopper species (specifically organo-Cu
I
, Cu
II
, and Cu
III 
intermediates) have been implicated in many reactions such as the Chan-Evans-Lam coupling,
101
 
Ullmann-Goldberg coupling,
102
 and an aromatic Glaser-Hay-type coupling.
103
  Oxidative 
insertion of Cu
I
 or transmetallation and subsequent oxidation with an external oxidant (often 
molecular O2) to generate an organo-Cu
III
 intermediate can be attacked by a nucleophile and 
43 
reductively eliminate the desired coupling product.  This type of process has been used to access 
α-alkenylation products via reaction of an alkenyl-CuIII intermediate with a wide variety of 
activated methylene compounds (Scheme 23).
104
  
   
 
 Scheme 23.  Copper-Catalyzed Coupling of Alkenyl Bromides with Activated Methylene Compounds 
 
     MacMillan and coworkers have used a combination of transition metal and 
organocatalysis to effect several challenging transformations.
98, 100a
  Initial forays in the area of 
α-alkenylation were extensions of previous work to develop synergistic catalysis protocols that 
afforded α-arylation105 and α-trifluoromethylation106 products with high enantioinduction.  Much 
of the early work used hypervalent iodine reagents (in particular, iodonium salts) which could be 
manipulated easily via transition metal or photoredox catalysis.  Thus, the first α-alkenylation 
procedure using synergistic catalysis utilized iodonium triflate salts and aldehydes under organo- 
and copper catalysis conditions to generate α-alkenyl aldehydes in high enantiomeric excess and 
good yield (scheme 24).  The transformation was postulated to proceed via oxidative insertion of 
Cu
I
 into the carbon-iodine bond of 2-17 to give alkenyl Cu
III
 species 2-18 which could then be 
attacked by nucleophilic enamine 2-20 derived from condensation of imidazolidinone salt 2-19 
with an aldehyde.  The resulting organometallic species can reductively eliminate to give a 
regenerated Cu
I
 catalyst and iminium ion 2-21 which can be hydrolyzed to give the desired α-
alkenylation product 2-22. 
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Scheme 24.  α-Alkenylation of Aldehydes with Vinyl Iodonium Triflates Using Copper and 
Organocatalysis  
 
 A later report by MacMillan and Stevens utilized readily prepared alkenyl boronic 
acids
100a
 with organo- and copper catalysis that could deliver the same class of compounds in 
comparable yields and selectivity.  In this case, boronic acid 2-23 can transmetallate with Cu
II
 
and be oxidized by O2 to arrive at the same putative alkenyl Cu
III
 species 2-25 as before (Scheme 
25).  Nucleophilic attack by transiently generated enamine 2-27 and subsequent reductive 
elimination gives iminium ion 2-28.  Hydrolysis gives 2-29 and regenerates organocatalyst 2-26.  
A broad range of substrates including electron-deficient and electron-rich substrates could be 
used and the reaction conditions were functionally simple.  This reactivity coupled with the 
ready accessibility of alkenyl boronic acids
107
 prompted us to examine this procedure as a better 
method of accessing amino acid 2-7 en route to XJB-5-131.      
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 Scheme 25. Mechanism of Enantioselective α-Alkenylation of Aldehydes Using Boronic Acids 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Synthetic Strategy towards Amino Acid 2-7 
We sought to take advantage of the high yielding peptide coupling steps that complete the 
synthesis of 2-2 and instead focus on constructing carboxylic acid 2-7 in a more efficient 
manner.  To that end, we envisioned that the previously discussed α-alkenylation using 
synergistic organocatalysis and copper catalysis
100a
 could be used to arrive at carboxylic acid 2-7 
(Figure 18).  Boronic acid 2-30 could be synthesized from commercially available N-Boc-leucine 
via hydrozirconation chemistry.  We also envisioned that using a model system 2-31 would 
allow us to probe the complexities of the key coupling step and answer several important 
questions.  First, while free N-H bonds have been used with MacMillan’s organocatalysis 
procedures,
108
 they have not been used in combination with metal catalysis in a vinylation 
procedure.  Second, while protected amines have been used in previous MacMillan alkenylation 
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procedures,
98-99
 protected allylic amines have not and can drastically change a substrate’s steric 
and electronic properties. 
 
   
Figure 18. New Synthetic Strategy Towards XJB-5-131 
 
2.2.2 Studies towards Amino Acid 2-7 
Initial studies were directed towards the synthesis of model system 2-31.  Boc protection 
of propargyl amine
109
 gave 2-32 in 85% yield which was subjected to a variety of hydroboration 
conditions that could be used to gain access to the desired boronic acid or the pinacolboronate 
ester.  Loss of the Boc protecting group was likely due to the formation of strong acids during 
the course of the reaction (Table 4, entries 1, 2, and 5).  All other hydroborating agents failed to 
give the desired product, presumably due to insufficient reactivity of the alkyne towards 
hydroboration, even when dialkylboranes were used (Table 4, entries 3-6).   
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Table 4. Attempted Hydroboration to Access a Substituted Boronic Acid 
 
   
 Ultimately, a zirconium-catalyzed hydroboration procedure modified from the original 
work of Pereira and Srebnik
110
 gave access to pinacolboronate ester 2-33 which decomposed 
when subjected to chromatography on SiO2 (Scheme 26).  The crude pinacolboronate ester was 
oxidatively cleavaged using NaIO4 and NH4OAc in aqueous acetone
111
 to give 2-34 which was 
also not isolable by chromatography on SiO2 due to decomposition.  Crystallization of the crude 
material from CH2Cl2 at -20 
o
C gave gram-scale quantities of 2-34 in 54% yield over 2 steps. 
 
 
 Scheme 26. Synthesis of Model Boronic Acid 2-34  
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 Boronic acid 2-38 could also be prepared via a similar route.  Alkyne 2-36 was prepared 
according to a two-step protocol involving formation of Weinreb amide 2-35 and a 
reduction/Ohira-Bestmann homologation sequence
112
 to give 2-36 (Scheme 27).  Preparing the 
Ohira-Bestmann reagent (2-39) in situ and subsequent reaction with the crude amino aldehyde 
(from LiAlH4 reduction)
112a
 gave lower yields (ca 30%) compared to preparing and isolating the 
reagent beforehand.
113
 Zirconium-catalyzed hydroboration of 2-36 followed by oxidative 
cleavage
111
 gave amino boronic acid 2-38 in 56% yield over 2 steps following crystallization 
from CH2Cl2.  Chiral imidazolidinones 2-40 and 2-41 (Figure 19) could be prepared according to 
literature protocols
114
 from the corresponding amino acids or purchased from commercial 
vendors.  The corresponding trifluoroacetate salts were prepared by treatment with TFA in Et2O.   
 
 
 Scheme 27. Synthesis of Amino Boronic Acid 2-38 
 
 
 Figure 19. Structure of Chiral Imidazolidinones 2-40 and 2-41 
 
 Initial attempts to alkenylate boronic acid 2-34 gave complex mixtures that were found to 
contain hydrocinnamyl alcohol, protodeboronation products, a mixed boronic anhydride 
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resulting from cyclodehydration with methylboronic acid and 2-34, and a small amount of 2-42 
(Table 5, entry 1).  Screening reaction conditions indicated the necessity of excess water in the 
reaction (even in the presence of molecular sieves) to achieve synthetically useful yields. 
Eventually a maximum yield of 33% (Table 5, entry 7) was achieved using 500 wt% of 4 Å 
molecular sieves and 30 mol% of 2-40 TFA salt, and allowing the reaction to proceed for two 
days at room temperature.  Attempts to use 2-34 as the limiting reagent gave significant amounts 
of protodeboronation product and no detectable amount of 2-42.  Heating the reaction mixture 
gave no product by 
1
H NMR and 3 Å molecular sieves in pellet form led to decreased yields.  
 
 Table 5. Conditions for α-Alkenylation with Boronic Acid 2-34 
 
 
 In addition, potassium trifluoroborate salt 2-43 was prepared to test its utility in both the 
synergistic catalysis protocol
100a
 and the previously described organo-SOMO procedure.
99
  
Zirconium-catalyzed hydroboration of 2-32 followed by treatment with aq. KHF2 gave 2-43 in 
63% yield (Scheme 28).  Organo-SOMO catalysis conditions using CAN as the oxidant gave no 
desired product while reaction under synergistic catalysis conditions gave the desired product in 
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comparable yield to 2-34 (13%, compare to Table 5, entry 1).  Exclusion of molecular sieves and 
methyl boronic acid gave no desired product, presumably due to insolubility of the 
trifluoroborate salt.  These results indicated that the electron-deficient nature of the olefinic 
reaction partner may disfavor formation of key electron-deficient intermediates (Scheme 25, 2-
25) and lead to low yields of desired product.  
 
 
Scheme 28.  Preparation of Potassium Trifluoroborate 2-43 and Organo-SOMO Vinylation 
 
 
Scheme 29.  Synergistic Catalysis Using Potassium Trifluoroborate 2-43 
 
 It was thought that the isobutyl chain of 2-38 would help to stabilize electron-deficient 
intermediates that are formed during the copper catalytic cycle.  Thus, boronic acid 2-38 was 
subjected to α-alkenylation conditions.  No desired product was obtained using our optimized 
reaction conditions.  Stoichiometric organocatalyst (Table 6, entry 2) and stoichiometric 
Cu(OAc)2 (Table 6, entry 3) were used but failed to deliver any detectable amount of alcohol 2-
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44.  Extended reaction times (Table 6, entry 4) did not give any trace of the desired product 
either even with stoichiometric organocatalyst.  Possibly there may be an unidentified effect of 
the protecting group effect that subtly modulates the reactivity of the boronic acid.  
 
 Table 6.  Attempted α-Alkenylation Using 2-38 
 
 
2.3 CONCLUSIONS 
 
A concise route to XJB-5-131 was explored that relied on the diastereoselective α-
alkenylation of hydrocinnamaldehyde with boronic acid 2-38.
100a
  Model system boronic acid 2-
34 was synthesized and used to explore various reaction parameters that could affect the 
transformation, including water content, limiting reagent, and the loading of molecular sieves.  A 
33% yield of alkenylation product 2-42 was obtained, indicating that the desired transformation 
is feasible but difficult to achieve.  Boronic acid 2-38 was synthesized starting from 
enantiomerically enriched N-Boc-leucine in 5 steps and 36% overall yield.  Attempts to use this 
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compound in the α-alkenylation procedure did not lead to desired product under a variety of 
conditions.   
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3.0  EXPERIMENTAL PART 
3.1 GENERAL EXPERIMENTAL 
All reactions were performed under an N2 atmosphere and all glassware was dried in an 
oven at 130 
o
C for at least 2 h prior to use and allowed to cool under an atmosphere of dry N2 or 
Ar unless otherwise stated.  Reactions carried out below 0 
o
C employed an acetone/dry ice bath 
or a cryocool and an acetone bath.  THF and Et2O were distilled over sodium/benzophenone 
ketyl, CH2Cl2 and toluene were distilled over CaH2, and 1,4-dioxane, MeOH, and MeCN were 
dried batchwise over 3 Å molecular sieves unless otherwise noted. Et3N and DIPEA were 
distilled from CaH2 and stored over KOH.  Concentration under reduced pressure refers to the 
use of a rotary evaporator connected to a PIAB Lab Vac H40 to remove solvent and drying under 
high vacuum refers to the use of a Fischer Scientific Maxima C Plus vacuum pump (0.5-4 
mmHg) to remove traces of solvent.    
All flash column chromatography was performed with normal phase SiO2 (Silicycle, 40-
63 μm particle size). Reactions were monitored by thin-layer chromatography (Merck pre-coated 
silica gel 60 F254 plates, 250 μm layer thickness) and visualization was accomplished with a 254 
nm UV light, by staining with KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL 
of a 0.1% NaOH solution), or by staining with p-anisaldehyde solution (2.5 mL of p-
anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. H2SO4 in 100 mL of 95% EtOH). 
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Melting points were obtained using a Laboratory Devices Mel-Temp II using open 
capillaries and are uncorrected. 
1
H and 
13
C NMR spectra were obtained on Bruker Avance 300, 
400, or 500 instruments as indicated. 
1
H spectra were obtained at 300, 400, or 500 MHz in 
CDCl3 and (CD3)2SO unless otherwise noted.  Chemical shifts were reported in parts per million 
with the residual solvent peak used as an internal standard.  
1
H NMR spectra were obtained and 
are tabulated as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, quint = quintet, dd = double of doublets, dt = doublet of triplets, m = multiplet, br = 
broad, app = apparent), number of protons, and coupling constant(s).  
13
C NMR were run at 75, 
100, 125, or 175 MHz as specified using a proton-decoupled pulse sequence and are tabulated by 
observed peak.  Infrared spectra were measured on a PerkinElmer Spectrum100 FT-IR 
Spectrometer (ATR).  High resolution mass spectra were obtained on a Thermo Fisher Exactive 
Orbitrap LC-MS using heated electrospray ionization (HESI).  Compounds 2-39
113
, 2-40, and 2-
41
114
 were prepared according to literature protocols. 
3.2 CHAPTER 1 EXPERIMENTAL PART 
 
1-16 
(4-Amino-3-nitrophenyl)[(4-pentafluorothiophenyl)methyl]amine (1-16).  To a 
solution of 2-nitro-p-phenylenediamine (0.751 g, 4.66 mmol) and PTSA (0.045 g, 0.24 mmol) in 
toluene (25 mL) was added 4-(pentafluorothio)-benzaldehyde (1.115 g, 4.707 mmol).  The 
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resulting solution was heated to reflux with a Dean-Stark trap for 21 h, the mixture was filtered 
through a Buchner funnel packed with a thin pad of SiO2, and the filtrate was stirred and allowed 
to cool to rt. The solvent was removed under reduced pressure to give the crude imine (1.10 g) as 
a bright orange-red solid, that was suspended in a mixture of 1,4-dioxane (5.2 mL) and MeOH 
(1.3 mL) and NaBH4 (0.120 g, 3.14 mmol) was added in 3 portions at 15 min intervals. The 
resulting solution was allowed to stir at rt for 3 h, quenched with H2O (25 mL) and the resulting 
solid collected by filtration. The crude compound was washed with H2O (500 mL) and dried 
under high vacuum to give 1 (1.09 g, 2.95 mmol, 63%) as a dark purple powder: Mp 129-130 
o
C 
(H2O); IR (ATR) 3522.90, 3397.94, 1576.91, 1531.83, 1327.68, 1216.31 cm
-1
; 
1
H NMR (CDCl3, 
400 MHz) δ 7.73 (d, 2 H, J = 8.4 Hz), 7.61 (d, 2 H, J = 8.4 Hz), 7.27 (d, 1 H, 2.8 Hz), 6.84 (dd, 1 
H, J = 9.2, 2.8 Hz), 6.71 (d, 1 H, J = 8.8 Hz), 5.74 (br s, 2 H), 4.37 (s, 2 H), 3.92 (br s, 1 H); 
13
C 
NMR (CDCl3, 100 MHz) δ 153.2 (app. t, J = 17.5 Hz), 143.0, 138.9, 138.5, 132.6, 127.7, 126.5 
(quint., J = 4.6 Hz), 125.3, 120.4, 106.2, 48.1; HRMS (HESI) m/z calcd for C13H13N3O2F5S 
(M+H) 370.0643, found 370.0645.   
 
 
1-17 
(4-Amino-3-nitrophenyl)[(3-pentafluorothiophenyl)methyl]amine (1-17). A solution 
of 2-nitro-p-phenylenediamine (0.756 g, 4.69 mmol) and PTSA (0.054 g, 0.28 mmol) in toluene 
(25 mL) was treated with 3-(pentafluorothio)benzaldehyde (1.10 g, 4.56 mmol) via syringe and 
the resulting solution was heated to reflux with a Dean-Stark trap for 5 h. The mixture was 
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filtered through a Buchner funnel packed with a thin pad of SiO2 and the filtrate was stirred and 
allowed to cool to rt. The solvent was removed under reduced pressure to give the crude imine 
(1.571 g) as a bright orange-red solid, that was suspended in a mixture of 1,4-dioxane (5.2 mL) 
and MeOH (1.3 mL) and NaBH4 (0.126 g, 3.30 mmol) was added in 3 portions at 15 min 
intervals. The resulting solution was allowed to stir at rt for 3 h, quenched with H2O (25 mL), 
and extracted from brine with CH2Cl2 (3 x 200 mL). The solvent was removed under reduced 
pressure and the resulting residue dried under high vacuum at 60 
o
C for 12 h to give 1-17 (1.36 g, 
3.69 mmol, 79%) as a dark red-purple powder: Mp 128-129 
o
C (CH2Cl2); IR (ATR) 3477.56, 
3422.45, 3360.67, 3109.99, 1574.79, 1515.17, 1206.56; 
1
H NMR (CDCl3, 400 MHz) δ 7.77 (s, 1 
H), 7.68 (d, 1 H, J = 8.4 Hz), 7.53 (d, 1 H, 7.6 Hz), 7.47-7.43 (m, 1 H), 7.30 (d, 1 H, J = 2.8 Hz), 
6.86 (dd, 1 H, J = 8.8, 2.8 Hz), 6.72 (d, 1 H, J = 8.8 Hz), 5.75 (br s, 2 H), 4.37 (s, 2 H), 3.89 (br 
s, 1 H); 
13
C NMR (CDCl3, 100 MHz) 154.4 (quint., J = 18.0 Hz), 140.3, 139.0, 138.5, 132.6, 
130.7, 129.3, 125.4, 125.3-125.1 (overlapping quint.), 120.4, 106.4, 48.6; HRMS (HESI) m/z 
calcd for C13H13N3O2F5S (M+H) 370.0643, found 370.0641. 
 
 
 
1-18 
(4-Amino-3-nitrophenyl){[4-(trifluoromethyl)phenyl]methyl}amine (1-18).  A 
solution of 2-nitro-p-phenylenediamine (0.754 g, 4.68 mmol) and PTSA (0.054 g, 0.28 mmol) in 
toluene (25 mL) was treated via syringe with 4-(trifluoromethyl)benzaldehyde (0.640 mL, 4.69 
mmol) and the resulting solution was heated at reflux with a Dean-Stark trap for 5 h. The mixture 
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was filtered through a Buchner funnel packed with a thin pad of SiO2 and the filtrate was stirred 
and allowed to cool to rt. The solvent was removed under reduced pressure to give the crude 
imine (1.23 g) as a bright orange-red solid, that was suspended in a mixture of 1,4-dioxane (5.2 
mL) and MeOH (1.3 mL) and NaBH4 (0.120 g, 3.14 mmol) was added in 3 portions at 15 min 
intervals. The resulting solution was allowed to stir at rt for 3 h, quenched with H2O (25 mL) and 
extracted from brine with CH2Cl2 (3 x 200 mL). The solvent was removed under reduced 
pressure and the residue dried under high vacuum at 60 
o
C to give 1-18 (1.141 g, 3.666 mmol, 
78%) as a dark purple oil: IR (CH2Cl2) 3483.58, 3370.03, 1573.93, 1521.07, 1324.97 cm
-1
; 
1
H 
NMR (CDCl3, 400 MHz) δ 7.60 (d, 2 H, J = 8.0 Hz), 7.48 (d, 2 H, J = 8.0 Hz), 7.28 (d, 1 H, J = 
2.8 Hz), 6.85 (dd, 1 H, J = 8.8, 2.8 Hz), 6.71 (d, 1 H, J = 8.8 Hz), 5.47 (br s, 2 H), 4.37 (s, 2 H), 
3.92 (br s, 1 H); 
13
C NMR (CDCl3 100 MHz) δ 143.1, 139.1, 138.4, 132.6, 129.9 (q, J = 32.1 
Hz), 127.8, 125.8 (q, J = 3.6 Hz), 125.3, 124.2 (q, J = 270.0 Hz), 120.3, 106.1, 48.5; HRMS 
(HESI) m/z calcd for C14H13N3O2F3 (M+H) 312.0954, found 312.0955. 
 
 
1-19 
(4-Amino-3-nitrophenyl){[3-(trifluoromethyl)phenyl]methyl}amine (1-19).  A 
solution of 2-nitro-p-phenylenediamine (0.753 g, 4.67 mmol) and PTSA (0.050 g, 0.26 mmol) in 
toluene (25 mL) was treated via syringe with 3-(trifluoromethyl)benzaldehyde (0.620 mL, 4.64 
mmol).  The resulting solution was heated to reflux with a Dean-Stark trap for 5 h, filtered 
through a Buchner funnel packed with a thin pad of SiO2, and allowed to cool to rt.  The solvent 
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was removed under reduced pressure to give the crude imine (1.203 g) as bright orange solid, 
that was suspended in a mixture of 1,4-dioxane (3.7 mL) and MeOH (0.90 mL) and NaBH4 
(0.117 g, 0.655 mmol) was added in 3 portions at 15 minute intervals. The resulting solution was 
allowed to stir at rt for 3 h, quenched with H2O (25 mL), and extracted with CH2Cl2 (3 x 100 
mL). The combined organic extracts were washed with brine, dried (Na2SO4), filtered, and the 
solvent evaporated under reduced pressure to give crude 1-19 (1.141 g). Purification by 
chromatography on SiO2 (70% CH2Cl2 in hexanes) gave 1-19 (1.10 g, 3.35 mmol, 72%) as a dark 
purple powder: Mp 95-96 
o
C (CH2Cl2); IR (ATR) 3456.00, 3396.67, 3330.69, 1515.08, 1323.54 
cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.64 (s, 1 H), 7.55 (m, 2 H), 7.47 (m, 1 H), 7.29 (d, 1 H, J = 
2.8 Hz), 6.86 (dd, 1 H, J = 8.8, 2.8 Hz), 6.71 (d, 1 H, J = 8.8 Hz), 5.74 (br s, 2 H), 4.36 (s, 2 H), 
3.89 (br s, 1 H); 
13
C NMR (CDCl3, 100 MHz) δ 140.0, 139.16, 138.5, 132.6, 131.2 (q, J = 32 
Hz), 131.0, 129.3, 125.4, 124.5 (q, J = 3.7 Hz), 124.4 (q, J = 3.8 Hz), 124.2 (q, J = 271 Hz), 
120.3, 106.2, 48.6; HRMS (ESI) m/z calcd for C14H13N2O3F3 (M+H) 312.0954, found 312.0947. 
 
 
1-20 
N-(4-Amino-3-nitrophenyl)(phenylmethoxy)-N-{[4-(pentafluorothio)phenyl]methyl} 
carboxamide (1-20). A solution of 1-16 (0.207 g, 0.544 mmol) and DIPEA (0.110 mL, 0.665 
mmol) in 1,4-dioxane (2.8 mL) at rt was treated dropwise via syringe with benzyl chloroformate 
(0.100 mL, 0.682 mmol). The resulting solution was allowed to stir for 18 h and was then 
quenched with 1:1 H2O:CH2Cl2 (6.5 mL). The phases were separated and the aqueous phase 
extracted with CH2Cl2 (3 x 5 mL). The combined organic phases were washed with brine, dried 
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(Na2SO4), filtered, and the solvent evaporated to give crude 1-20 (0.280 g) as an orange foam 
that was used without further purification. 
 
 
1-21 
N-(4-Amino-3-nitrophenyl)(phenylmethoxy)-N-{[3-(pentafluorothio)phenyl]methyl} 
carboxamide (1-21). A solution of 1-17 (0.202 g, 0.531 mmol) and DIPEA (0.090 mL, 0.54 
mmol) in 1,4-dioxane (2.8 mL) at rt was treated dropwise via syringe with benzyl chloroformate 
(0.080 mL, 0.55 mmol). The resulting solution was allowed to stir for 3 h and was then quenched 
with 6.50 mL of 1:1 H2O:CH2Cl2. The phases were separated and the aqueous phase extracted 
with CH2Cl2 (3 x 5 mL). The combined organic phases were washed with brine, dried (Na2SO4), 
filtered, and the solvent evaporated to give crude 1-21 (0.309 g) as an orange oil which was used 
without further purification. 
 
 
1-22 
N-(4-Amino-3-nitrophenyl)(phenylmethoxy)-N-{[4-(trifluoromethyl)phenyl]methyl} 
carboxamide (1-22).  A solution of 1-18 (0.199 g, 0.639 mmol) and DIPEA (0.110 mL, 0.666 
mmol) in 1,4-dioxane (3.2 mL) at rt was treated dropwise via syringe with benzyl chloroformate 
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(0.100 mL, 0.682 mmol). The resulting solution was allowed to stir for 4 h and was then 
quenched with 1:1 H2O:CH2Cl2 (6.5 mL). The phases were separated and the aqueous phase 
extracted with CH2Cl2 (3 x 5 mL). The combined organic phases were washed with brine, dried 
(Na2SO4), filtered, and the solvent evaporated to give crude 1-22 (0.328 g) as a dark orange oil 
which was used without further purification. 
 
 
1-23 
N-(4-Amino-3-nitrophenyl)(phenylmethoxy)-N-{[3-(trifluoromethyl)phenyl]methyl} 
carboxamide (1-23). A solution of 1-19 (0.205 g, 0.659 mmol) and DIPEA (0.115 mL, 0.696 
mmol) in 1,4-dioxane (3.5 mL) at rt was treated dropwise via syringe with benzyl chloroformate 
(0.100 mL, 0.682 mmol).  The resulting solution was allowed to stir for 4 h at rt and was then 
quenched with 1:1 H2O:CH2Cl2 (10 mL), the layers were separated, and the aqueous phase was 
extracted with CH2Cl2 (2 x 15 mL). The combined organic phases were washed with H2O and 
brine, dried (Na2SO4), filtered, and the solvent evaporated to give crude 1-23 (0.331 g) as an 
orange oil which was used without further purification. 
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1-24 
Ethoxy-N-(4-{N-[(4-
pentafluorothiophenyl)methyl](phenylmethoxy)carbonylamino}-2-
nitrophenyl)carboxamide (1-24). A solution of crude 1-20 (0.050 g, 0.099 mmol) and DIPEA 
(0.050 mL, 0.30 mmol) in 1,4-dioxane (1.0 mL) at rt was treated dropwise via syringe with ethyl 
chloroformate (0.030 mL, 0.31 mmol).  The resulting solution was allowed to stir at 70 
o
C for 24 
h and was then quenched with 1:1 H2O:CH2Cl2 (5 mL). The phases were separated and the 
aqueous phase extracted with CH2Cl2 (3 x 20 mL). The combined organic phases were washed 
with H2O and brine, dried (MgSO4), filtered, and the solvent evaporated under reduced pressure 
to give crude 1-24 (0.050 g) as an orange oil. The crude residue was purified by chromatography 
on SiO2 (30% EtOAc in hexanes) to give 1-24 (0.036 g, 0.063 mmol, 63%, 82% brsm) as an 
orange oil: IR (CH2Cl2) 3365.79, 2094.66, 1738.05, 1706.74, 1515.21 cm
-1
; 
1
H NMR (CDCl3, 
400 MHz) δ 9.77 (s, 1 H), 8.54 (d, 1 H, J = 9.2 Hz), 8.04 (br s, 1 H), 7.68 (d, 2 H, J = 8.8 Hz), 
7.33-7.27 (m, 5 H), 7.24-7.22 (m, 2 H), 5.19 (s, 2 H), 4.92 (s, 2 H), 4.26 (q, 2 H, J  = 7.2 Hz), 
1.34 (t, 3 H, J = 7.2 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 155.2, 153.4 (quint., J = 18.0 Hz),153.2, 
153.2, 141.0, 135.8, 135.7, 134.2, 128.8, 128.8, 128.2, 127.9, 126.6 (app. t, J = 4.6 Hz), 123.6, 
121.4, 68.5, 62.3, 53.4, 14.5; HRMS (HESI) m/z calcd for C24H23N3O6F5S (M+H) 576.1222, 
found 576.1221.    
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1-25 
Ethoxy-N-(4-{N-[(4-
pentafluorothiophenyl)methyl](phenylmethoxy)carbonylamino}-2-
nitrophenyl)carboxamide (1-25). A solution of crude 1-21 (0.326 g), DIPEA (0.280 mL, 1.69 
mmol), and DMAP (0.003 g, 0.02 mmol) in 1,4-dioxane (4 mL) at rt was treated dropwise via 
syringe with ethyl chloroformate (0.155 mL, 1.58 mmol).  The resulting solution was allowed to 
stir at 70 
o
C for 2 d and was then quenched by the addition of 1:1 H2O:CH2Cl2 (10 mL). The 
phases were separated and the aqueous phase extracted with CH2Cl2 (3 x 20 mL). The combined 
organic phases were washed with H2O, 1 M aq. HCl, and brine, dried (MgSO4), filtered, and the 
solvent evaporated under reduced pressure to give crude 1-25 (0.340 g) as an orange oil. The 
crude residue was purified by chromatography on SiO2 (20% EtOAc in hexanes) to give 1-25 
(0.052 g) as a yellow oil which was used without further purification. 
 
 
1-26 
63 
Ethoxy-N-[2-nitro-4-((phenylmethoxy)-N-{[4-(trifluoromethyl)phenyl]methyl} 
carbonylamino)phenyl]carboxamide (1-26). A solution of crude 1-22 (0.310 g) and DIPEA 
(0.670 mL, 4.05 mmol) in 1,4-dioxane (5.2 mL) at rt was treated dropwise via syringe with ethyl 
chloroformate (0.395 mL, 4.03 mmol).  The resulting solution was allowed to stir at 70 
o
C for 3 d 
and was then quenched by the addition of 1:1 H2O:CH2Cl2 (10 mL). The phases were separated 
and the aqueous phase extracted with CH2Cl2 (3 x 20 mL). The combined organic phases were 
washed with H2O and brine, dried (Na2SO4), filtered, and the solvent evaporated under reduced 
pressure to give crude 1-26 (0.350 g) as an orange solid. The crude solid was purified by 
chromatography on SiO2 (20% EtOAc in hexanes) to give 1-26 (0.194 g, 0.375 mmol, 59% over 
2 steps) as an orange oil: IR (CH2Cl2) 3365.80, 2983.18, 1738.22, 1706.37, 1514.40, 1323.26 
cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz, 353 K) δ 9.50 (br s, 1 H), 7.96 (d, 1 H, J = 2.4 Hz), 7.77 
(d, 1 H, J = 8.8 Hz), 7.64 (d, 1 H, J = 8.4 Hz), 7.60 (dd, 1 H, J  = 8.8, 2.4 Hz), 7.48 (d, 1 H, J = 
8.0 Hz), 7.33-7.26 (m, 7 H), 5.19 (s, 2 H), 5.05 (s, 2 H), 4.15 (q, 2 H, J = 7.2 Hz), 1.24 (t, 3 H, J 
= 7.2 Hz); 
13
C NMR (DMSO-d6, 100 MHz, 353 K) δ 154.2, 152.9, 141.8, 140.0, 136.8, 135.8, 
131.8, 130.3, 128.0, 127.9, 127.7, 127.5, 127.1, 124.9 (q, J = 3.7 Hz), 123.8 (q, J = 270.3 Hz), 
123.8, 122.5, 67.0, 60.8, 52.3, 13.8; HRMS (HESI) m/z calcd for C25H21N3O6F3 (M-H) 516.1377, 
found 516.1372. 
 
 
1-27 
64 
Ethoxy-N-[2-nitro-4-((phenylmethoxy)-N-{[3-(trifluoromethyl)phenyl]methyl} 
carbonylamino)phenyl]carboxamide (1-27). A solution of crude 1-23 (0.330 g) and DIPEA 
(0.545 mL, 3.30 mmol) in 1,4-dioxane (5 mL) at rt was treated dropwise via syringe with ethyl 
chloroformate (0.160 mL, 1.63 mmol).  The resulting solution was allowed to stir at 70 
o
C for 2 d 
and was then quenched by the addition of 1:1 H2O:CH2Cl2 (10 mL), the layers were separated 
and the aqueous phase was extracted with CH2Cl2 (2 x 20 mL). The combined organic phases 
were washed with H2O (2 x 20 mL) and brine (2 x 10 mL), dried (MgSO4), filtered, and the 
solvent evaporated under reduced pressure to give crude 1-27 (0.310 g) as an orange oil. The 
crude oil was purified by chromatography on SiO2 (20% EtOAc in hexanes) to give 1-27 (0.113 
g) as a yellow oil which was carried on without further purification. 
 
 
1-5 
N-[2-amino-4-({[4-
(pentafluorothio)phenyl]methyl}amino)phenyl]ethoxycarboxamide (1-5). A solution of 1-24 
(0.047 g, 0.082 mmol) and 10% Pd/C (0.010 g, 0.009 mmol, 10 mol%) in a mixture of 1,4-
dioxane (0.46 mL) and EtOH (0.24 mL) was allowed to stir for 21 h at rt under an H2 atmosphere 
(balloon). The reaction mixture was diluted with Et2O (5 mL) and filtered through a pad of 
Celite. The organic phase was concentrated under reduced pressure to give crude 1-5 (0.037 g) as 
an orange oil. The crude oil was purified by chromatography on SiO2 (50% EtOAc in hexanes) 
to give 1-5 (0.018 g, 0.044 mmol, 54%) as a light brown solid: Mp 146-147 
o
C (CH2Cl2); IR 
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(ATR) 3377.56, 2925.72, 1697.84, 1620.85, 1525.67 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.70 
(d, 2 H, J = 8.4 Hz), 7.43 (d, 2 H, J = 8.4 Hz), 6.92 (d, 1 H, J = 8.4 Hz), 6.02 (dd, 1 H, J = 8.4, 
2.4 Hz), 5.95 (d, 1 H, J = 2.4 Hz), 4.35 (s, 2 H), 4.18 (q, 2 H, J = 7.2 Hz), 3.90 (br s, 2 H), 1.28 
(t, 3 H, J = 7.2 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 155.6, 152.9 (quint., J = 13.5 Hz), 147.4, 
143.9, 142.2, 128.1, 127.3, 126.4 (quint., J = 4.0 Hz), 114.5, 104.5, 100.8, 61.5, 47.6, 14.7; 
HRMS (HESI) m/z calcd for C16H19N3O2F5S (M+H) 412.1113, found 412.1111. 
 
 
1-6 
N-[2-Amino-4-
({[3(pentafluorothio)phenyl]methyl}amino)phenyl]ethoxycarboxamide (1-6). A solution of 
1-25 (0.050 g, 0.087 mmol) and 10% Pd/C (0.010 g, 0.010 mmol) in 1,4-dioxane (0.46 mL) and 
EtOH (0.24 mL) was allowed to stir under an H2 atmosphere (balloon) for 18 h. The reaction 
mixture was diluted with Et2O (5 mL) and filtered through a pad of Celite. The solvent was 
removed under reduced pressure to give crude 1-6 (0.049 g) as an orange oil. The crude residue 
was purified by chromatography on SiO2 (50% EtOAc in hexanes) to give 1-6 (0.027 g, 0.066 
mmol, 76%) as a light brown oil that solidified on standing: Mp 52-53 
o
C (CH2Cl2); IR (ATR) 
3355.44, 2931.13, 1699.36, 1623.12, 1525.18, 1229.40 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.73 
(s, 1 H), 7.65 (d, 1 H, J = 8.0 Hz), 7.50 (d, 1 H, J = 7.6 Hz), 7.42 (app. t, 1 H, J = 7.8 Hz), 6.92 
(d, 1 H, J = 8.4 Hz), 6.04 (dd, 1 H, J = 8.0, 2.0 Hz), 5.98 (d, 1 H, J = 2.0 Hz), 4.34 (s, 2 H), 4.18 
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(q, 2 H, J = 7.1 Hz), 3.85 (br s, 2 H), 1.28 (t, 3 H, J = 7.2 Hz); 
13
C NMR (CDCl3, 175 MHz) δ 
155.6, 154.4 (quint., J = 16.8 Hz), 147.4, 143.1, 141.1, 130.4, 129.1, 128.0, 124.9 (quint., J = 4.2 
Hz), 124.8 (quint., J = 4.4 Hz), 114.5, 104.5, 100.9, 61.5, 48.1, 14.7; HRMS (HESI) m/z calcd 
for C16H19N3O2F5S (M+H) 412.1113, found 412.1101. 
 
 
1-7 
N-[2-Amino-4-({[4-
(trifluoromethyl)phenyl]methyl}amino)phenyl]ethoxycarboxamide (1-7). A solution of 1-26 
(0.090 g, 0.174 mmol) and 10% Pd/C (0.018 g, 0.017 mmol) in a mixture of 1,4-dioxane (1 mL) 
and EtOH (0.50 mL) was allowed to stir at rt for 18 h under an H2 atmosphere (balloon). The 
reaction mixture was diluted with Et2O (5 mL) and filtered through a pad of Celite. The organic 
phase was concentrated under reduced pressure to give crude 1-7 (0.051 g) as a light brown 
solid. The crude solid was purified by chromatography on SiO2 (50% EtOAc in hexanes) to give 
1-7 (0.044 g, 0.12 mmol, 72%) as a grey solid: Mp 171-172 
o
C (CH2Cl2); IR (ATR) 3279.60, 
2980.62, 1677.20, 1526.96 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.59 (d, 2 H, J = 8.4 Hz), 7.46 
(d, 2 H, J = 8.0 Hz), 6.92 (d, 1 H, J = 8.4 Hz), 6.05 (dd, 1 H, J = 8.4, 2.4 Hz), 5.98 (d, 1 H, J = 
2.4 Hz), 4.37 (s, 2 H), 4.19 (q, 2 H, J = 7.2 Hz), 4.06 (br s, 1 H), 3.74 (br s, 2 H), 1.28 (t, 3 H, J = 
7.0 Hz); 
13
C NMR (CDCl3, 100 MHz δ 155.7, 147.6, 143.9, 143.2, 129.6 (q, J = 32.0 Hz), 128.1, 
127.5, 125.7 (q, J = 3.7 Hz), 124.3 (q, J = 270.2 Hz), 114.3, 104.5, 100.6, 61.5, 48.0, 14.8; 
HRMS (HESI) m/z calcd for C17H19N3O2F3 (M+H) 354.1424, found 354.1425.  
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1-8 
N-[2-Amino-4-({[3-
(trifluoromethyl)phenyl]methyl}amino)phenyl]ethoxycarboxamide (1-8). A suspension of 
impure 1-27 (0.100 g, 0.193 mmol) and 10% Pd/C (0.020 g, 0.018 mmol, 10 mol%) in 1,4-
dioxane (1 mL) and EtOH (0.50 mL) was allowed to stir at rt for 18 h under an H2 atmosphere 
(balloon). The reaction mixture was diluted with Et2O, filtered through a pad of Celite, and the 
solvent removed under reduced pressure to give crude 1-8 (0.067 g) as a dark brown oil. The 
crude oil was purified by chromatography on SiO2 (50% EtOAc in hexanes) to give 1-8 (0.056 g, 
0.16 mmol, 24% over 3 steps) as an off-white solid: Mp 103-104 
o
C (CH2Cl2); IR (ATR) 
3335.08, 2987.62, 1723.51, 1679.79, 1535.27 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.61 (s, 1 H), 
7.53 (app. t, 2 H, J = 7.0 Hz), 7.46-7.42 (m, 1 H), 6.92 (d, 1 H, J = 8.0 Hz), 6.05 (dd, 1 H, J = 
8.4, 2.4 Hz), 5.98 (d, 1 H, J = 2.4 Hz), 4.34 (s, 2 H), 4.19 (q, 2 H, J = 7.2 Hz), 3.76 (br s, 2 H), 
1.28 (t, 3 H, J = 7.2 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 155.6, 147.6, 143.2, 140.8, 131.1 (q, J = 
32.0 Hz), 130.7, 129.2, 128.0, 124.3 (q, J = 270.9 Hz), 124.2-124.1 (overlapping q.), 114.3, 
104.5, 100.8, 61.5, 48.1, 14.7; HRMS (HESI) m/z calcd for C17H19N3O2F3 (M+H) 354.1424, 
found 354.1421.   
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1-29 
(4-Amino-3-nitrophenyl)(2,2,2-trifluoro-1-phenylethyl)amine (1-29). A solution of 2-
nitro-p-phenylenediamine (0.504 g, 3.13 mmol) and PTSA (0.034 g, 0.17 mmol) in toluene (15 
mL) at rt was treated with 2,2,2-trifluoroacetophenone (0.544 g, 3.09 mmol) and was stirred at 
reflux for 24 h with a Dean-Stark trap. The reaction mixture was filtered through a pad of SiO2 
and the solvent evaporated under reduced pressure to give the crude imine (0.170 g), which was 
suspended in 1,4-dioxane (4 mL) and MeOH (1 mL) and NaBH4 (0.125 g, 3.27 mmol) was 
added in 3 portions at 15 minute intervals. The resulting solution was allowed to stir at rt for 3 h. 
H2O (25 mL) was added and solution was extracted with CH2Cl2 (3 x 20 mL). The organic phase 
was dried (Na2SO4), filtered, and the solvent evaporated under reduced pressure.  Further drying 
under high vacuum gave 1-29 (0.120 g, 0.386 mmol, 12%) as a dark red solid: Mp 126-127 
o
C 
(CH2Cl2); IR (ATR) 3436.04, 3387.95, 333.42, 1581.30, 1514.40, 1326.05, 1237.64; 
1
H NMR 
(CDCl3, 400 MHz) δ 7.44-7.38 (m, 5 H), 7.33 (d, 1 H, J = 2.8 Hz), 6.89 (dd, 1 H, J = 9.2, 2.8 
Hz), 6.69 (d, 1 H, J = 8.8 Hz), 5.75 (br s, 2 H), 4.84 (m, 1 H), 4.13 (d, 1 H, J = 7.6 Hz); 
13
C 
NMR (CDCl3, 100 MHz) δ 139.2, 136.6, 133.6, 132.3, 129.51, 129.2, 128.0, 126.0, 125.1 (q, J = 
280.3 Hz), 120.3, 108.6, 61.4 (q, J = 30.0 Hz); HRMS (HESI) m/z calcd for C14H13N3O2F3 
(M+H) 312.0954, found 312.0953.  
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1-31 
Ethoxy-N-{2-nitro-4-[(2,2,2-trifluoro-1-phenylethyl)amino]phenyl}carboxamide (1-
31).  A solution of 1-29 (0.060 g, 0.19 mmol) and DIPEA (0.065 mL, 0.39 mmol) in 1,4-dioxane 
(1.3 mL) at rt was treated dropwise via syringe with ethyl chloroformate (0.020 mL, 0.20 mmol). 
The resulting solution was allowed to stir at 50 
o
C for 18 h and was then quenched by the 
addition of 1:1 H2O:CH2Cl2 (10 mL).  The layers were separated and the aqueous phase was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic phases were washed with H2O (2 x 10 
mL) and brine (2 x 10 mL), dried (Na2SO4), filtered, and the solvent evaporated under reduced 
pressure to give crude 1-31 (0.100 g) as an orange-red oil. The crude solid was purified by 
chromatography on SiO2 (40-60% CH2Cl2 in hexanes) to give 1-31 (0.054 g, 0.14 mmol, 73%) as 
a red oil: IR (CH2Cl2) 3372.96, 2983.93, 1718.95, 1523.09, 1324.06 cm
-1
; 
1
H NMR (CDCl3, 500 
MHz) δ 9.39 (s, 1 H), 8.30 (d, 1 H, J = 9.0 Hz), 7.46-7.40 (m, 6 H), 6.98 (dd, 1 H, J = 9.5, 2.2 
Hz), 4.91 (m, 1 H), 4.56 (br d, 1 H, J = 7.0 Hz), 4.22 (q, 2 H, J = 7.0 Hz), 1.31 (t, 3 H, J = 7.0 
Hz); 
13
C NMR (CDCl3, 125 MHz) δ 153.6, 140.7, 137.0, 133.1, 129.6, 129.3, 128.0, 127.7, 124.9 
(q, J = 280.5 Hz), 122.7, 122.6, 121.5, 108.8, 61.9, 60.6 (q, J = 30.4 Hz), 14.5; HRMS (HESI) 
m/z calcd for C17H17N3O4F3 (M+H) 384.1166, found 384.1163. 
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1-10 
N-{2-Amino-4-[(2,2,2-trifluoro-1-phenylethyl)amino]phenyl}ethoxycarboxamide (1-
10). A suspension of 1-31 (0.050 g, 0.13 mmol) and 10% Pd/C (0.014 g, 0.013 mmol) was 
allowed to stir under an H2 atmosphere (balloon) for 18 h. The reaction mixture was diluted with 
Et2O, filtered through Celite, and the solvent evaporated under reduced pressure to give crude 1-
10 (0.066 g) as a gray oil. The crude residue was purified by chromatography on SiO2 (0-10% 
EtOAc in CH2Cl2) to give 1-10 (0.041 g, 0.12 mmol, 89%) as a clear, colorless oil that solidified 
upon standing: Mp 51-52 
o
C (CH2Cl2); IR (ATR) 3346.05, 2984.78, 1696.03, 1524.18 cm
-1
; 
1
H 
NMR (CDCl3, 400 MHz) δ 7.42-7.37 (m, 5 H), 6.90 (d, 1 H, J = 8.0 Hz), 6.05 (app. d, 1 H, J = 
8.4 Hz), 6.01 (app. s, 1 H), 4.84 (m, 1 H), 4.28 (d, 1 H, J = 7.2 Hz), 4.17 (q, 2 H, J = 7.1 Hz), 
3.72 (br s, 2 H), 1.27 (t, 3 H, J = 6.6 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 155.5, 145.3, 143.0, 
134.2, 129.2, 129.0, 128.0, 125.1 (q, J = 280.2 Hz), 115.5, 105.2, 102.1, 61.5, 60.7 (q, J = 29.8 
Hz), 14.7; HRMS (HESI) m/z calcd for C17H19N3O2F3 (M+H) 354.1424, found 354.1422.   
 
 
 
1-32 
(4-Fluorophenyl)-N-methoxy-N-methylcarboxamide (1-32).
1
 A solution of 
methoxymethylamine hydrochloride (0.634 g, 6.37 mmol) and Et3N (0.860 mL, 6.12 mmol) in 
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CH2Cl2 (3.75 mL) at 0 
o
C was treated dropwise via syringe with 4-fluorobenzoyl chloride (0.370 
mL, 3.07 mmol) over 30 min and the resulting solution was allowed to stir at rt for 2 h. The 
reaction mixture was poured into H2O and extracted with CH2Cl2 (3 x 20 mL). The organic 
extracts were washed with brine, dried (MgSO4), and the solvent removed under reduced 
pressure.  Further drying under high vacuum gave crude 1-32 (0.672 g, 2.63 mmol, quant.) which 
was used without further purification: 
1
H NMR (CDCl3, 400 MHz) δ 7.74 (m, 2 H), 7.08 (m, 2 
H), 3.53 (s, 3 H), 3.36 (s, 3 H); HRMS (HESI) m/z calcd for C9H11NO2F (M+H) 184.0768, found 
184.0768. 
 
 
1-33 
4-Fluorobenzaldehyde-d (1-33). To a solution of 1-33 (0.062 g, 0.338 mmol) in THF 
(1.9 mL) at -78 
o
C was added LiAlD4 (0.018 g, 0.42 mmol) portionwise and the mixture was 
stirred for 2 h at the same temperature. The reaction mixture was quenched with H2O at -78 
o
C, 
Et2O was added, and the precipitate removed by filtration through a pad of Celite. The filtrate 
was washed with H2O and brine, dried (Na2SO4), and concentrated under reduced pressure. 
Further drying under high vacuum for 1 h gave 0.032 g crude 1-33 as a pale yellow oil which 
was used without further purification. 
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1-34 
(4-Amino-3-nitrophenyl)[(4-fluorophenyl)methyl]amine-d2 (1-34). A solution of 2-
nitro-p-phenylenediamine (0.602 g, 3.73 mmol), PTSA (0.040 g, 0.21 mmol) and crude 1-33 
(0.273 g) was heated to reflux with a Dean-Stark trap for 18 h. The solution was filtered through 
a thin pad of SiO2 and the solvent evaporated under reduced pressure to give the crude imine 
(0.328 g) which was suspended in 1,4-dioxane (4 mL) and MeOH (1 mL) and NaBD4 (0.111 g, 
2.60 mmol) was added in 3 portions at 15 minute intervals. The resulting solution was allowed to 
stir at rt for 3 h and was then quenched with H2O (25 mL) and filtered to give 1-34 (0.241 g, 
0.915 mmol, 42% over 2 steps) as a dark purple powder: Mp 113-114 
o
C (H2O); IR (ATR) 
3517.22, 3496.96, 3371.18, 1577.41, 1502.47, 1329.45 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 
7.34-7.27 (m, 3 H), 7.28 (d, 1 H, J = 2.4 Hz), 7.03 (t, 2 H, J = 8.6 Hz), 6.84 (dd, 1 H, J = 8.8, 2.4 
Hz), 5.75 (br s, 2 H), 3.80 (br s, 1 H); 
13
C NMR (CDCl3, 100 MHz) δ 162.3 (d, J = 244.0 Hz), 
139.4, 138.3, 134.5 (d, J = 3.0 Hz), 132.5, 129.3 (d, J = 8.0 Hz), 125.5, 120.2, 115.7 (d,  J = 21.3 
Hz), 105.9, 47.7 (t, J = 20.6 Hz); HRMS (HESI) m/z calcd for C13H11D2N3O2F (M+H) 264.1112, 
found 264.1110. 
 
 
1-35 
N-(4-Amino-3-nitrophenyl)-N-[(4-
fluorophenyl)methyl](phenylmethoxy)carboxamide-d2 (1-35). A solution of 1-34 (0.100 g, 
0.380 mmol) and DIPEA (0.095 mL, 0.58 mmol) in 1,4-dioxane (1.9 mL) at rt was treated 
dropwise via syringe with benzyl chloroformate (0.060 mL, 0.41 mmol). The resulting solution 
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was allowed to stir at rt for 18 h and was then quenched by the addition of 1:1 H2O:CH2Cl2 (10 
mL).  The layers were separated and the aqueous phase extracted with CH2Cl2 (3 x 10 mL). The 
combined organic phases were washed with H2O (2 x 10 mL) and brine (2 x 10 mL), dried 
(Na2SO4), filtered, and the solvent evaporated under reduced pressure to give crude 1-35 (0.220 
g) as an orange-yellow oil which was used without further purification. 
 
 
1-36 
Ethoxy-N-(4-{N-[(4-fluorophenyl)methyl](phenylmethoxy)carbonylamino}-2-
nitrophenyl)carboxamide-d2 (1-36). A solution of crude 1-35 (0.220 g) and DIPEA (0.190 mL, 
1.15 mmol) in 1,4-dioxane (3.5 mL) at rt was treated dropwise via syringe with ethyl 
chloroformate (0.090 mL, 0.92 mmol).  The resulting solution was allowed to stir at 70 
o
C for 2 d 
and was then quenched by the addition of 1:1 H2O:CH2Cl2 (20 mL).  The layers were separated 
and the aqueous phase extracted with CH2Cl2 (2 x 10 mL). The combined organic phases were 
washed with 1 M aq. HCl (2 x 10 mL) and brine (2 x 10 mL), dried (MgSO4), filtered, and the 
filtrate concentrated under reduced pressure. Further drying under high vacuum gave crude 1-36 
(0.320 g) as an orange-yellow solid. The crude solid was purified by chromatography on SiO2 
(20% EtOAc in hexanes) to give 1-36 (0.100 g, 0.213 mmol, 56%) as a yellow oil: IR (CH2Cl2) 
3364.46, 2981.47, 1738.36, 1702.40, 1509.76, 1331.36; 
1
H NMR (CDCl3, 400 MHz) δ 9.77 (s, 1 
H), 8.51 (d, 1 H, J = 8.8 Hz), 7.99 (br s, 1 H), 7.36-7.30 (m, 4 H), 7.27-7.25 (m, 2 H), 7.17-7.13 
(m, 2 H), 6.96 (tt, 2 H, J = 8.6, 2.3 Hz), 5.19 (s, 2 H), 4.26 (q, 2 H, J = 7.0 Hz), 1.34 (t, 3 H, J = 
74 
7.0 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 162.4 (d, J = 245.0 Hz), 155.2, 153.1, 136.0, 135.7, 
134.7, 134.0, 132.6 (d, J = 3.2 Hz), 129.7, 128.7, 128.4, 128.1, 123.9, 121.1, 115.7 (d, J = 21.3 
Hz), 68.1, 62.2, 52.8 (br), 14.5; HRMS (HESI) m/z calcd for C24H19D2N3O6F (M-H) 468.1534, 
found 468.1545.  
 
 
1-9 
N-(2-Amino-4-{[(4-fluorophenyl)methyl]amino}phenyl)ethoxycarboxamide-d2 (1-9). 
A suspension of 1-36 (0.095 g, 0.196 mmol) and 10% Pd/C (0.022 g, 0.020 mmol) in 1,4-
dioxane (1.1 mL) and EtOH (0.60 mL) was allowed to stir at rt under an H2 atmosphere (balloon) 
for 18 h. The solution was diluted with Et2O (5 mL), filtered through a pad of Celite, and the 
solvent evaporated under reduced pressure to give crude 1-9 (0.078 g) as a light brown oil. The 
crude residue was purified by chromatography on SiO2 (55% EtOAc in hexanes) to give 1-9 
(0.045 g, 0.147 mmol, 75%) as a light brown solid: Mp 142-143 
o
C (CH2Cl2); IR (ATR) 
3394.70, 3342.61, 2987.36, 1675.57, 1506.24 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.32 – 7.28 
(m, 2 H), 7.01 (app. t, 2 H, J = 8.6 Hz), 6.91 (d, 1 H, J  = 8.4 Hz), 6.04 (dd, 1 H, J = 8.4, 2.4 Hz), 
5.98 (d, 1 H, J = 2.4 Hz), 4.18 (q, 2 H, J  = 7.0 Hz), 3.78 (br s, 2 H), 1.28 (t, 3 H, J = 7.0 Hz); 
13
C 
NMR (CDCl3, 100 MHz) 162.1 (d, J = 243.0 Hz), 155.7, 147.8, 143.1, 135.1 (d, J = 3.0 Hz), 
129.0 (d, J = 8.0 Hz), 128.0, 115.5 (d, J = 21.2 Hz), 114.1, 104.4, 100.8, 61.5, 47.1 (t, J = 20.6 
Hz), 14.7; HRMS (HESI) m/z calcd for C16H17D2N3O2F (M+H) 306.1581, found 306.1584. 
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1-37 
(4-Amino-3-nitrophenyl)(2-thienylmethyl)amine (1-37). A solution of thiophene-2-
carboxaldehyde (0.125 mL, 1.34 mmol), 2-nitro-p-phenylenediamine (0.210 g, 1.30 mmol), 
PTSA (0.035 g, 0.18 mmol), and 4 Å mol. sieves (1.063 g) in CH2Cl2 (3.1 mL) and MeOH (3.1 
mL) was allowed to stir at rt for 5 h. The resulting solution was filtered through Celite and the 
solvent removed under reduced pressure to give a dark brown solid that was dissolved in CH2Cl2 
(20 mL), filtered through a thin pad of SiO2 eluting with the same solvent, and concentrated 
under reduced pressure to give crude imine (0.250 g) as a bright orange solid. The solid was 
suspended in 1,4-dioxane (1.5 mL) and MeOH (0.50 mL), NaBH4 (0.070 g, 1.83 mmol was 
added in 3 portions at 15 min intervals, and the resulting solution was allowed to stir at rt for 20 
h. The reaction mixture was quenched by the addition of 1:1 H2O:CH2Cl2 (30 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic layers were washed with H2O (2 x 10 mL) and brine (2 x 10 mL), dried (Na2SO4), 
filtered, and the solvent evaporated under reduced pressure. Further drying under high vacuum at 
50 
o
C gave 1-37 (0.230 g, 0.923 mmol, 71%) as a dark red solid: Mp 103-105 
o
C (CH2Cl2); IR 
(ATR) 3506.46, 3380.50, 3115.96, 1576.61, 1518.86, 1332.92 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) 
δ 7.37 (d, 1 H, J = 2.8 Hz), 7.23 (dd, 1 H, J = 4.8, 1.2 Hz), 7.03-7.02 (m, 1 H), 6.97 (dd, 1 H, J = 
5.2, 3.6 Hz), 6.88 (dd, 1 H, J = 8.8, 2.8 Hz), 6.71 (d, 1 H, J = 8.8 Hz), 5.74 (br s, 2 H), 4.48 (s, 2 
H), 3.83 (br s, 2 H); 
13
C NMR (CDCl3, 100 MHz) δ 142.2, 139.0, 138.5, 132.6, 127.1, 125.6, 
125.6, 125.0, 120.2, 106.6, 44.2; HRMS (HESI) m/z calcd for C11H12N3O2S (M+H) 250.0645, 
found 250.0644. 
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1-39 
(4-Amino-3-nitrophenyl)(1,3-thiazol-2-ylmethyl)amine (1-39). A solution of 2-
thiazolecarboxaldehyde (0.115 mL, 1.27 mmol), 2-nitro-p-phenylenediamine (0.209 g, 1.30 
mmol), PTSA (0.025 g, 0.13 mmol), and 4 Å mol. sieves (1.15 g) in CH2Cl2 (3.1 mL) and MeOH 
(3.1 mL) was allowed to stir for 18 h at rt. The resulting solution was filtered through Celite and 
the solvent removed under reduced pressure to give a dark brown solid. This solid was 
suspended in CH2Cl2 (20 mL), filtered through a thin pad of SiO2 eluting with the same solvent, 
and the solvent removed under reduced pressure to give crude imine (0.205 g) as a bright orange 
solid.  The solid was suspended in 1,4-dioxane (2 mL) and MeOH (0.75 mL), NaBH4 (0.035 g, 
0.92 mmol) was added in a single portion, and the resulting solution was allowed to stir at rt for 
8 h. The reaction mixture was quenched by the addition of 1:1 H2O:CH2Cl2 (15 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic layers were washed with H2O (2 x 10 mL) and brine (2 x 10 mL), dried (Na2SO4), 
filtered, and the solvent evaporated under reduced pressure. Further drying under high vacuum at 
50 
o
C overnight gave 1-39 (0.194 g, 0.775 mmol, 61%) as a dark red solid: Mp 161-162 
o
C 
(CH2Cl2); IR (ATR) 3469.82, 3380.19, 3349.79, 1584.11, 1518.80, 1384.29, 1330.62 cm
-1
; 
1
H 
NMR (DMSO-d6, 500 MHz) δ 7.74 (d, 1 H, J = 3.0 Hz), 7.58 (d, 1 H, J = 3.0 Hz), 7.04 (br s, 2 
H), 7.02 (d, 1 H, J = 3.0 Hz), 6.99 (d, 1 H, J = 2.5 Hz), 6.90 (d, 1 H, J = 9.0 Hz), 6.39 (t, 1 H, J = 
6.0 Hz), 4.54 (d, 2 H, J = 6.0 Hz); 
13
C NMR (DMSO-d6, 125 MHz) δ 171.8, 142.4, 140.1, 138.2, 
77 
129.9, 126.5, 120.4, 119.9, 103.0, 45.6; HRMS (HESI) m/z calcd for C10H11N4O2S (M+H) 
251.0597, found 251.0595. 
 
 
1-11 
N-{2-Amino-4-[(2-thienylmethyl)amino]phenyl}ethoxycarboxamide (1-11). A 
suspension of 1-37 (0.104 g, 0.334 mmol, 80% purity) and 10% Pd/C (0.035 g, 0.032 mmol) in 
1,4-dioxane (1.7 mL) and EtOH (0.70 mL) was allowed to stir at rt for 16 h under an H2 
atmosphere. The reaction mixture was diluted with Et2O, filtered through a pad of Celite, and the 
solvent evaporated under reduced pressure. Further drying under high vacuum gave the crude 
aryl triamine (0.093 g) as a dark yellow oil.  A solution of crude aryl triamine (0.093 g) and Et3N 
(0.080 mL, 0.57 mmol) in CH2Cl2 (1.2 mL) at rt was treated dropwise via syringe over 15 min 
with a solution of 1-41 (0.050 g, 0.21 mmol) in CH2Cl2 (1.2 mL). The resulting solution was 
allowed to stir at rt for 18 h, the solvent was evaporated under reduced pressure, the crude 
residue dissolved in EtOAc (20 mL), and washed with sat. aq. NaHCO3 (5 x 10 mL).  The 
aqueous washes were extracted with EtOAc (2 x 20 mL) and the combined organic phases were 
dried (MgSO4), filtered, and the solvent evaporated under reduced pressure to give crude 1-11 
(0.200 g) as a brown-green oil. The crude residue was purified by chromatography on SiO2 (5-
10% EtOAc in CH2Cl2) to give 1-11 (0.037 g, 0.13 mmol, 60%) as a gray oil that solidified upon 
standing: Mp 95-96 
o
C (CH2Cl2); IR (ATR) 3403.37, 3287.93, 1677.01, 1518.63 cm
-1
; 
1
H NMR 
(CDCl3, 500 MHz) δ 7.20 (dd, 1 H, J = 5.0, 1.5 Hz), 6.99 (app. d, 1 H, J = 2.5 Hz), 6.96 (dd, 1 H, 
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J = 5.0, 3.5 Hz), 6.93 (d, 1 H, J = 8.5 Hz), 6.09 (dd, 1 H, J = 8.3, 2.5 Hz), 6.04 (d, 1 H, J = 2.5 
Hz), 4.44 (s, 2 H), 4.19 (q, 2 H, J = 7.0 Hz), 3.82 (br s, 3 H), 1.28 (t, 3 H, J = 6.5 Hz); 
13
C NMR 
(CDCl3, 125 MHz) δ 155.6, 147.4, 143.1, 127.8, 127.0, 125.1, 124.7, 114.5, 104.7, 101.2, 61.5, 
43.7, 14.7; HRMS (HESI) m/z calcd for C14H18N3O2S (M+H) 292.1120, found 292.1109. 
 
 
1-12 
N-{2-Amino-4-[(1,3-thiazol-2-ylmethyl)amino]phenyl}ethoxycarboxamide (1-12). A 
suspension of 1-39 (0.072 g, 0.29 mmol) and Pd/C (0.028 g, 0.026 mmol) was allowed to stir 
under an H2 atmosphere (balloon) for 18 h. The reaction mixture was diluted with Et2O (10 mL) 
and filtered through a pad of Celite. The solvent was removed under reduced pressure to give the 
crude aryl triamine (0.076 g) as a dark red oil which was used without further purification.  A 
solution of the crude aryl triamine (0.076 g) and Et3N (0.075 mL, 0.53 mmol) in CH2Cl2 (1.00 
mL) at rt was treated dropwise via syringe over 10 min with a solution of 1-41 (0.061 g, 0.26 
mmol) in CH2Cl2 (1.10 mL).  The resulting solution was allowed to stir for 18 h, the solvent was 
evaporated under reduced pressure, the crude residue dissolved in EtOAc (20 mL), and washed 
with sat aq. NaHCO3 (4 x 20 mL) until the washes were clear. The aqueous washes were 
extracted with EtOAc (2 x 20 mL) and the combined organic fractions were washed with H2O (2 
x 20 mL) and brine (2 x 20 mL), dried (MgSO4), filtered, and the solvent evaporated under 
reduced pressure to give crude 1-12 (0.060 g) as a brown-red oil. The crude residue was purified 
by chromatography on SiO2 (70% EtOAc in hexanes) to give 1-12 (0.045 g, 0.15 mmol, 59% 
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over 2 steps) as a blue-green oil that solidified upon standing: Mp 46-47 
o
C (CH2Cl2); IR 
(CH2Cl2) 3352.87, 2981.33, 1696.90, 1621.12, 1523.21 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.72 
(d, 1 H, J = 3.2 Hz), 7.24 (d, 1 H, J = 3.2 Hz), 6.91 (d, 1 H, J = 8.4 Hz), 6.16 (br s, 1 H), 6.08 
(dd, 1 H, J = 8.4, 2.4 Hz), 6.02 (d, 1 H, J = 2.4 Hz), 4.59 (s, 2 H), 4.17 (q, 2 H, J = 7.2 Hz), 3.81 
(br s, 2 H), 1.27 (t, 3 H, J = 6.8 Hz); 
13
C NMR (CDCl3, 400 MHz) δ 171.6, 155.7, 146.8, 143.1, 
142.7, 127.9, 119.2, 114.8, 104.7, 101.2, 61.5, 46.5, 14.7; HRMS (HESI) m/z calcd for 
C13H17N4O2S (M+H) 293.1067, found 293.1063. 
 
 
1-41 
Ethyl (1,3-dioxobenzo[c]azolidin-2-yloxy)formate (1-41).
115
 A suspension of 
diphthalimidyl carbonate (0.382 g, 1.08 mmol) and EtOH (0.065 mL, 1.1 mmol) in THF (2.5 
mL) was treated with Et3N (0.150 mL, 1.07 mmol). Upon addition of base, the suspension turned 
yellow progressing to orange over 30 min. The reaction mixture was stirred for 5 h and the 
solvent evaporated. The residue was dissolved in EtOAc (25 mL) and washed with sat. aq. 
NaHCO3 (5 x 10 mL) until the organic layer became clear. The combined aqueous washings 
were extracted with EtOAc (2 x 20 mL). The combined organic layers were dried (MgSO4), 
filtered, and the solvent evaporated under reduced pressure.  Further drying under high vacuum 
gave 1-41 (0.230 g, 0.978 mmol, 90%) as a light yellow solid: 
1
H NMR (CDCl3, 300 MHz) δ 
7.90-7.84 (m, 2 H), 7.81-7.76 (m, 2 H), 4.40 (q, 2 H, J = 7.2 Hz), 1.40 (t, 3 H, J = 7.2 Hz); 
13
C 
NMR (CDCl3, 75 MHz) δ 161.6, 152.4, 135.0, 128.8, 124.1, 67.7, 14.1. 
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1-2 
(4-Amino-3-nitrophenyl)[(4-fluorophenyl)methyl]amine (1-2). A solution of 2-nitro-p-
phenylenediamine (0.998 g, 6.19 mmol) and 3 Å mol. sieves (3.00 g) in xylenes (30 mL) was 
heated to 90 
o
C and treated with 4-fluorobenzaldehyde (0.690 mL, 6.27 mmol). The resulting 
solution was allowed to stir for 20 h, filtered through a short pad of SiO2, allowed to cool for 6 h, 
and the solid precipitate filtered off to give the crude imine (0.719 g), that was dissolved in 1,4-
dioxane (4 mL) and MeOH (1 mL) and NaBH4 (0.157 g, 4.11 mmol) was added in 3 batches at 
15 min intervals. The solution was stirred for 10 h, quenched with H2O (25 mL), and the solid 
filtered to give 1-2 (0.573 g, 2.19 mmol, 35%): Mp 113-114 
o
C; IR (ATR) 3517.98, 3497.88, 
3395.77, 3372.60, 1578.67, 1503.24, 1406.73, 1329.96 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.33 
(app. dd, 2 H, J = 5.4, 2.2 Hz), 7.30 (d, 1 H, J = 2.8 Hz), 7.04 (app. t, 2 H, J = 8.6 Hz), 6.84 (dd, 
1 H, J = 8.8, 2.8 Hz), 6.70 (d, 1 H, J = 8.8 Hz), 5.73 (br s, 2 H), 4.26 (d, 2 H, J = 4.0 Hz); 
13
C 
NMR (CDCl3, 100 MHz) δ 162.3 (d, J = 245.0 Hz), 139.4, 138.3, 134.6 (d, J = 2.9 Hz), 132.6, 
129.4 (d, J = 8.0 Hz), 125.4, 120.2, 115.7 (d, J = 22.0 Hz), 106.1, 48.4; HRMS (HESI) m/z calcd 
for C13H13N3O2F (M+H) 262.0986, found 262.0981.  
 
 
1-42 
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N-(4-Amino-3-nitrophenyl)-N-
[(4fluorophenyl)methyl](phenylmethoxy)carboxamide (1-42). A solution of 1-2 (0.207 g, 
0.792 mmol) and DIPEA (0.140 mL, 0.848 mmol) in 1,4-dioxane (4 mL) at rt was treated 
dropwise via syringe with benzyl chloroformate (0.120 mL, 0.819 mmol).  The resulting solution 
was allowed to stir at rt for 5 h and was then quenched with 1:1 H2O:CH2Cl2 (6.5 mL). The 
phases were separated and the aqueous phase extracted with CH2Cl2 (3 x 5 mL). The combined 
organic phases were washed with brine, dried (Na2SO4), filtered, and the solvent evaporated 
under reduced pressure to give crude 1-42 (0.420 g) as an orange oil which was used without 
further purification. 
 
 
1-43 
N-(4-{N-[(4-Fluorophenyl)methyl](phenylmethoxy)carbonylamino}-2-nitrophenyl) 
(methylethoxy)carboxamide (1-43). A solution of crude 1-42 (0.415 g) and DIPEA (0.390 mL, 
2.36 mmol) in 1,4-dioxane (6.00 mL) at rt was treated dropwise via syringe with a solution of 
isopropyl chloroformate in toluene (1.95 mL, 1.95 mmol, 1.0 M).  The resulting solution was 
allowed to stir at 70 
o
C for 2 d and was then quenched by the addition of 1:1 H2O: CH2Cl2 (10 
mL), the layers were separated, and the aqueous phase extracted with CH2Cl2 (3 x 10 mL). The 
combined organic phases were washed with water and brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure to give crude 1-43 (0.410 g) as a dark orange oil. The crude 
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oil was purified by chromatography on SiO2 (10% EtOAc in hexanes) to give 1-43 (0.097 g) as a 
yellow oil along with recovered starting material (0.140 g). The starting material was recycled 
through the reaction procedure again to give 1-43 (0.050 g, 0.147 g total, 0.305 mmol, 39% over 
two steps) as a yellow oil: IR (CH2Cl2) 3367.42, 2982.20, 1735.01, 1705.36, 1510.64, 1338.30 
cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 9.72 (s, 1 H), 8.52 (d, 1 H, J = 8.8 Hz), 7.98 (br s, 1 H), 
7.36-7.25 (m, 5 H), 7.15 (app. t, 2 H, J = 6.8 Hz), 6.96 (t, 2 H, J = 8.8 Hz), 5.19 (s, 2 H), 5.08-
4.96 (m, 2 H), 4.84 (s, 2 H), 1.32 (d, 6 H, J = 6.4 Hz); 
13
C NMR (CDCl3, 100 MHz) δ 162.4 (d, J 
= 245.0 Hz), 155.3, 152.8, 136.0, 135.7, 134.7, 134.2, 132.8 (d, J = 3.2 Hz), 129.8, 128.7, 128.4, 
128.1, 124.0, 121.1, 115.8 (d, J = 21.3 Hz); HRMS (HESI) m/z calcd for C25H24N3O6F (M-H) 
480.1565, found 480.1575. 
 
 
 
1-44 
N-(2-Amino-4-{[(4-fluorophenyl)methyl]amino}phenyl)(methylethoxy)carboxamide 
(1-44). A suspension of 1-43 (0.049 g, 0.10 mmol) and 10% Pd/C (0.013 g, 0.012 mmol, 10 
mol%) in 1,4-dioxane (0.60 mL) and EtOH (0.30 mL) was allowed to stir at rt for 18 h under an 
H2 atmosphere (balloon). The reaction mixture was diluted with Et2O (5 mL), filtered through 
Celite, and the solvent evaporated under reduced pressure to give crude 1-43 (0.033 g) as a 
brown oil. The crude oil was purified by chromatography on SiO2 (50% EtOAc in hexanes) to 
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give 1-43 (0.024 g, 0.076 mmol, 74%) as an off-white solid: Mp 171-172 
o
C (CH2Cl2); IR (ATR) 
3396.44, 3342.93, 3289.29, 2981.70, 1674.75; 
1
H NMR (CDCl3, 400 MHz) δ 7.31 (app. dd, 2 H, 
J = 8.4, 5.6 Hz), 7.01 (app. t, 2 H, J = 10.2 Hz), 6.92 (d, 1 H, J = 8.0 Hz), 6.06 (dd, 1 H, J = 8.4, 
2.4 Hz), 6.00 (d, 1 H, J = 2.4 Hz), 4.97 (m, 1 H), 4.25 (s, 2 H), 3.81 (br s, 2 H), 1.27 (d, 6 H, J = 
6.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 162.2 (d, J = 244.0 Hz), 155.3, 147.7, 143.1, 135.3 (d, J 
= 2.9 Hz), 129.1 (d, J = 7.9 Hz), 127.8, 115.6 (d, J = 21.2 Hz), 114.4, 104.5, 100.8, 68.9, 47.8, 
22.3; HRMS (HESI) m/z calcd for C17H21N3O2F (M-H) 318.1612, found 318.1611. 
 
 
1-45 
(3,4-Diaminophenyl)[(4-fluorophenyl)methyl]amine (1-45). A suspension of 1-2 
(0.101 g, 0.321 mmol) and 10% Pd/C (0.035 g, 0.032 mmol) in 1,4-dioxane (1.6 mL) and EtOH 
(0.80 mL) was allowed to stir at rt under an H2 atmosphere (balloon) for 18 h. The reaction 
mixture was diluted with Et2O (10 mL), filtered through a pad of celite, and the solvent 
evaporated under reduced pressure. Further drying under high vacuum gave crude 1-45 (0.077 g) 
as a brown oil which was used without further purification. 
 
 
1-14 
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N-(2-Amino-4-{[(4-fluorophenyl)methyl]amino}phenyl){2-[(3-methyloxetan-3-
yl)sulfinyl] ethoxy}carboxamide (1-14). A solution of crude 1-45 (0.062 g, 0.27 mmol) and 
Et3N (0.070 mL, 0.50 mmol) in CH2Cl2 (1.00 mL) was treated dropwise via syringe over 10 min 
with a solution of crude 1-47 (0.095 g, 0.26 mmol) in CH2Cl2 (1.00 mL).  The resulting solution 
was allowed to stir for 18 h at rt, the solvent was evaporated under reduced pressure, the residue 
dissolved in EtOAc (20 mL), and washed with sat. aq. NaHCO3 (3 x 10 mL). The combined 
aqueous layers were extracted with EtOAc (2 x 20 mL) and the combined organic layers were 
dried (MgSO4), filtered, and the solvent evaporated under reduced pressure to give crude 1-14 
(0.090 g) as a dark green oil. The crude residue was purified by chromatography on SiO2 (3-5% 
MeOH in CH2Cl2) to give 1-14 (0.041 g, 0.094 mmol, 39% over two steps) as a light brown oil: 
IR (CH2Cl2) 3362.88, 2256.98, 1712.79, 1619.15, 1525.30, 1508.32 cm
-1
; 
1
H NMR (DMSO-d6, 
500 MHz, 323 K) δ 7.99 (br s, 1 H), 7.38-7.35 (m, 2 H), 7.09 (t, 2 H, J = 8.8 Hz), 6.73 (d, 1 H, J 
= 8.5 Hz), 5.99 (d, 1 H, J = 2.0 Hz), 5.88 (dd, 1 H, J = 8.5, 2.5 Hz), 5.56 (s, 1 H), 4.64 (d, 1 H, J 
= 5.5 Hz), 4.55 (d, 1 H, J = 5.5 Hz), 4.45-4.31 (m, 5 H), 4.24 (d, 1 H, J = 6.0 Hz), 4.19 (d, 2 H, J 
= 4.5 Hz), 3.19-3.13 (m, 2 H), 3.03-3.00 (m, 2 H), 1.49 (s, 3 H); 
13
C NMR (DMSO-d6, 125 MHz, 
323 K) δ 160.7 (d, J = 240.0 Hz), 154.2, 147.1, 143.2, 136.4, 128.5 (d, J = 7.5 Hz), 126.9, 114.3 
(d, J = 21.3 Hz), 112.7, 101.7, 98.9, 90.0, 80.6, 59.8, 56.7, 51.7, 45.9, 37.6, 23.0; HRMS (HESI) 
m/z calcd for C21H27N3O4FS (M+H) 436.1701, found 436.1698. 
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1-15 
N-(2-Amino-4-{[(4-fluorophenyl)methyl]amino}phenyl)[(3-methyloxetan-3-
yl)methoxy] carboxamide (1-15). A solution of crude 1-45 (0.077 g) and Et3N (0.090 mL, 0.64 
mmol) in CH2Cl2 (1.30 mL) at rt was treated dropwise via syringe over 15 min with a solution of 
1-46 (0.101 g, 0.347 mmol) in CH2Cl2 (1.30 mL).  The resulting solution was allowed to stir for 
18 h, the solvent was evaporated under reduced pressure, the crude residue dissolved in EtOAc 
(20 mL), and washed with sat. aq. NaHCO3 (3 x 10 mL). The combined aqueous washes were 
extracted with EtOAc (2 x 20 mL) and the combined organic layers were dried (MgSO4), 
filtered, and the solvent evaporated under reduced pressure to give crude 1-15 (0.110 g) as an 
olive green oil. The crude oil was purified by chromatography on SiO2 (40-50% EtOAc in 
hexanes) to give 1-15 (0.033 g, 0.092 mmol, 29% over 2 steps) as a dark brown oil; IR (CH2Cl2) 
3346.52, 2960.42, 2876.96, 1701.71, 1619.50, 1524.48, 1508.10 cm
-1
; 
1
H NMR (CDCl3, 400 
MHz) δ 7.30 (dd, 2 H, J = 8.2, 5.4 Hz), 7.02 (app. t, 2 H, J = 8.6 Hz), 6.93 (d, 1 H, J = 7.6 Hz), 
6.21 (br s, 1 H), 6.06 (d, 1 H, J = 8.4 Hz), 6.00 (s, 1 H), 4.58 (app. br s, 2 H), 4.39 (app. br s, 2 
H), 4.25 (s, 2 H), 4.20 (s, 2 H), 3.80 (br s, 3 H), 1.35 (s, 3 H); 
13
C NMR (CDCl3, 100 MHz) δ 
161.2 (d, J = 243.0 Hz), 155.5, 147.9, 143.1, 135.2 (d, J = 3.0 Hz), 129.0 (d, J = 8.0 Hz), 127.9, 
115.6 (d, J = 21.0 Hz), 113.9, 104.6, 100.8, 79.6, 69.4, 47.7, 39.5, 21.3; HRMS (HESI) m/z calcd 
for C19H23N3O3F (M+H) 360.1723, found 360.1712. 
 
 
1-46 
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(3-Methyloxetan-3-yl)methyl (1,3-dioxobenzo[c]azolidin-2-yloxy)formate (1-46). A 
suspension of diphthalimidyl carbonate (0.381 g, 1.08 mmol) and 3-methyl-3-oxetanemethanol 
(0.110 mL, 1.08 mmol) in THF (5 mL) was treated with Et3N (0.160 mL, 1.14 mmol). Upon 
addition of base, the suspension turned yellow progressing to orange over 2 h. The reaction 
mixture was stirred for 14 h and the solvent was evaporated under reduced pressure. The residue 
was dissolved in EtOAc (25 mL) and washed with sat. aq. NaHCO3 (5 x 10 mL) until the organic 
layer became clear. The combined aqueous washings were extracted with EtOAc (2 x 20 mL). 
The combined organic layers were dried (MgSO4), filtered, and the solvent evaporated under 
reduced pressure. Further drying under high vacuum gave 1-46 (0.255 g, 0.876 mmol, 81%) as a 
clear, light yellow oil: IR (CH2Cl2) 2965.43, 2875.74, 1811.79, 1788.73, 1741.98 cm
-1
; 
1
H NMR 
(CDCl3, 400 MHz) δ 7.91-7.88 (m, 2 H), 7.81-7.79 (m, 2 H), 4.54 (d, 2 H, J = 6.4 Hz), 4.47 (s, 2 
H), 4.43 (d, 2 H, J = 6.0 Hz), 1.41 (s, 3 H); 
13
C NMR (CDCl3, 100 MHz) 161.5, 152.7, 135.1, 
128.8, 124.3, 79.1, 75.4, 39.5, 20.8; HRMS (HESI) m/z calcd for C14H14NO6 (M+H) 292.0816, 
found 292.0819. 
 
 
1-47 
2-{[(3-Methyloxetan-3-yl)methyl]sulfinyl}ethyl (1,3-dioxobenzo[c]azolidin-2-
yloxy)formate (1-47).
2
 A suspension of diphthalimidyl carbonate (0.380 g, 1.08 mmol) and 
MMS-350 sulfoxide alcohol (0.195 g, 1.09 mmol) in THF (5 mL) was treated with Et3N (0.145 
mL, 1.03 mmol). Upon addition of base, the suspension turned yellow, eventually progressing to 
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a clear orange solution after 20 min. The reaction mixture was stirred 2 h, and the solvent was 
evaporated. The residue was dissolved in EtOAc (25 mL) and washed with saturated aqueous 
NaHCO3 (5 x 3 mL) until the organic layer became clear. The combined aqueous washings were 
extracted with EtOAc (2 x 10 mL). The combined organics were dried (MgSO4) and the solvent 
evaporated under reduced pressure to give 1-47 (0.265 g, 0.721 mmol, 66%) as a foaming solid 
which was used without further purification. 
 
3.3 CHAPTER 2 EXPERIMENTAL PART 
 
 
 
2-32 
(tert-butoxy)-N-prop-2-ynylcarboxamide (2-32).
109
 A solution of propargylamine (4.00 
mL, 57.7 mmol) in CH2Cl2 (110 mL) at 0 
o
C was treated dropwise via syringe over 15 min with 
a solution of Boc2O (12.75 g, 57.84 mmol) in CH2Cl2 (5 mL). The resulting solution was allowed 
to stir for 2 h at 0 
o
C and the solvent was removed under reduced pressure. Further drying under 
high vacuum gave crude 2-32 as an orange oil. The crude oil was purified by chromatography on 
SiO2 (10% EtOAc in hexanes) to give 2-32 (7.641 g, 49.24 mmol, 85%) as a white, crystalline 
solid: Mp 39-41 
o
C; IR 3320.16, 3290.77, 2980.70, 1679.97, 1524.58 cm
-1
; 
1
H NMR (CDCl3, 
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300 MHz) δ 4.82 (br s, 1 H), 3.89 (d, 2 H, J = 3.3 Hz), 2.19 (t, 1 H, J = 2.6 Hz), 1.42 (s, 9 H); 
13
C NMR (CDCl3, 400 MHz) δ 155.4, 80.2, 80.1, 71.3, 30.5, 28.4.   
 
2-33 
(E)-tert-Butyl (3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate (2-33).  
A solution of 2-32 (5.02 g, 19.5 mmol) in THF (9.6 mL) at 0 
o
C was treated dropwise via syringe 
with pinacolborane (3.30 mL, 22.5 mmol) and the resulting solution was allowed to stir for 5 
min. The reaction mixture was transferred via syringe to a flask containing Schwartz’s reagent 
(0.540 g, 2.09 mmol) at 0 
o
C. The solution was allowed to stir at 50 
o
C for 22 h before being 
quenched with H2O (50 mL). The mixture was extracted with Et2O (2 x 75 mL) and the organic 
phase washed with H2O (2 x 15 mL), dried (MgSO4), filtered, and the solvent evaporated under 
reduced pressure to give crude 2-33 (5.91 g, 107% by mass) as a pale yellow solid-oil mixture 
which was used without further purification. 
 
 
2-34 
(E)-(3-((tert-Butoxycarbonyl)amino)prop-1-en-1-yl)boronic acid (2-34).  A 
suspension of crude 2-33 (3.419 g), NaIO4 (4.47 g, 20.9 mmol), and NH4OAc (1.86 g, 24.1 
mmol) in 1:1 acetone:H2O (110 mL) was allowed to stir for 18 h at rt. The slurry was diluted 
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with EtOAc (100 mL) and H2O (100 mL), the layers were separated, and the organic phase 
washed with H2O (3 x 30 mL). The organic layer was washed with brine (2 x 30 mL), dried 
(MgSO4), filtered, and the solvent evaporated under reduced pressure. The crude residue was 
crystallized from CH2Cl2 (20 mL) to give 2-34 (1.299 g, 6.462 mmol, 54% over 2 steps) as a 
white crystalline solid: Mp 113-117 
o
C (CH2Cl2); IR (ATR) 3294.50, 2981.18, 1685.52, 1641.37, 
1520.45 cm
-1
; 
1
H NMR (acetone-d6, 400 MHz) δ 6.73 (br s, 2 H), 6.50 (dt, 1 H, J = 18.0, 4.8 
Hz), 6.08 (br s, 1 H), 5.54 (app. d, 1 H, J = 18.0 Hz), 3.74 (t, 2 H, J = 4.8 Hz), 1.41 (s, 9 H); 
13
C 
NMR (acetone-d6, 100 MHz) δ 156.5, 148.0, 123.8 (br), 78.6, 44.7, 28.6; HRMS (HESI) m/z 
calcd for C4H8BNO4 (M-C4H9+H) 146.0619, found 146.0618. 
 
 
2-35 
(S)-tert-Butyl (1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (2-
35).
112a
  To a solution of N-Boc-L-leucine (3.13 g, 13.3 mmol), BOP (5.70 g, 12.9 mmol), and 
DIPEA (5.50 mL, 33.3 mmol) in CH2Cl2 (130 mL) was added N,O-dimethylhydroxylamine 
hydrochloride (1.74 g, 17.5 mmol) and the resulting solution was allowed to stir at rt for 36 h. 
The reaction mixture was diluted with EtOAc (50 mL) and washed consecutively with 1 M aq. 
HCl (2 x 100 mL), sat. aq. NaHCO3 (100 mL), and brine (100 mL). The organic phase was dried 
(MgSO4), filtered, and the solvent removed under reduced pressure to give crude 2-35 (6.46 g) as 
a clear gel. The crude gel was purified by chromatography on SiO2 (20% EtOAc in hexanes) to 
give 2-35 (3.35 g, 12.2 mmol, 95%) as a clear, colorless oil: [α]D -9.1 (c 1.0, CHCl3); 
1
H NMR 
(CDCl3, 300 MHz) δ 5.06 (d, 1 H, J = 9.0 Hz), 4.64 (br. s, 1 H), 3.71 (s, 3 H), 3.12 (s, 3 H), 1.71-
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1.56 (m, 1 H), 1.35 (app. s, 12 H), 0.88 (d, 3 H, J = 6.6 Hz), 0.85 (d, 3 H, J = 6.9 Hz); 
13
C NMR 
(CDCl3, 75 MHz) δ 173.9, 155.6, 79.4, 61.5, 49.0, 42.1, 32.2, 28.4, 24.7, 23.3, 21.6. 
 
 
 
2-36 
N-[(1S)-1-(2-Methylpropyl)prop-2-ynyl](tert-butoxy)carboxamide (2-36).
112b
  A 
solution of 2-35 (3.55 g, 12.9 mmol) in Et2O (85 mL) at 0 
o
C was treated dropwise via syringe 
with LiAlH4 (15.50 mL, 15.50 mmol, 1.0 M in Et2O). The resulting solution was allowed to stir 
at the same temperature for 2 h, then for 2 h at rt, and was then quenched by the dropwise 
addition of 5% aq. KHSO4 (15 mL). H2O (100 mL) was added, the phases were separated, and 
the aqueous phase extracted with Et2O (3 x 100 mL). The combined organic phases were dried 
(MgSO4), filtered, and the solvent was evaporated under reduced pressure to give crude amino 
aldehyde (3.42 g). The crude residue was dissolved in MeOH (35 mL) and added via syringe to a 
solution of K2CO3 (5.62 g, 39.9 mmol) and the Ohira-Bestmann reagent (3.82 g, 19.7 mmol) in 
MeCN (175 mL). The resulting solution was allowed to stir at rt for 18 h and the solvent was 
removed under reduced pressure. Et2O (150 mL) and H2O (150 mL) were added and the layers 
separated. The aqueous phase was extracted with Et2O (3 x 100 mL) and the combined organic 
phases were dried (MgSO4), filtered, and the solvent evaporated under reduced pressure to give 
crude 2-36 (2.71 g) as an orange oil. The crude residue was purified by chromatography on SiO2 
(10% EtOAc in hexanes) to give 2-36 (1.771 g, 8.381 mmol, 65%) as a clear, colorless oil: 
1
H 
NMR (CDCl3, 400 MHz) δ 4.63 (br. s, 1 H), 4.44 (br. d, 1 H, J = 6.4 Hz), 2.25 (d, 1 H, J = 2.4 
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Hz), 1.80 (app. hept., 1 H, J = 6.8 Hz), 1.59 (s, 1 H), 1.52 (t, 2 H, J = 7.6 Hz), 1.45 (s, 9 H), 0.94 
(d, 3 H, J = 6.4 Hz), 0.93 (d, 3 H, J = 6.8 Hz). 
 
 
2-37 
N-[(2E)(1S)-1-(2-Methylpropyl)-3-(4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-
yl))prop-2-enyl](tert-butoxy)carboxamide (2-37).  A solution of 2-36 (0.970 g, 4.59 mmol) in 
THF (2.5 mL) was treated dropwise via syringe with pinacolborane (0.775 mL, 5.34 mmol) and 
the resulting solution was allowed to stir for 5 min. The reaction mixture was transferred via 
syringe to a flask containing Schwartz’s reagent (0.192 g, 0.745 mmol) at 0 oC. The solution was 
allowed to stir at 50 
o
C for 22 h before being quenched with H2O (5 mL). The mixture was 
extracted with Et2O (3 x 50 mL), washed with H2O (2 x 50 mL), dried (MgSO4), filtered, and the 
solvent evaporated under reduced pressure to give crude 2-37 (1.47 g, 94% by mass) as a yellow 
oil which was used without further purification. 
 
 
2-38 
 (S,E)-(3-((tert-Butoxycarbonyl)amino)-5-methylhex-1-en-1-yl)boronic acid (2-
38).  A suspension of crude 2-38 (3.05 g), NaIO4 (3.65 g, 17.1 mmol) and NH4OAc (1.37 g, 17.8 
mmol) in 1:1 acetone:H2O (84 mL) was allowed to stir for 24 h at rt. The slurry was diluted with 
EtOAc (50 mL) and H2O (50 mL), the layers separated, and the organic phase extracted with 
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brine (3 x 30 mL). The organic layer was dried (MgSO4), filtered, and the solvent evaporated 
under reduced pressure. The crude residue was crystallized from CH2Cl2 (20 mL) at -20 
o
C to 
give 2-38 (1.214 g, 4.721 mmol, 56%) as a white, crystalline solid: [α]D -17.3 (c 1.0, MeOH); 
Mp 103-108 (decomp., CH2Cl2); IR (ATR) 3313.01, 2958.25, 2935.58, 1686.86, 1367.37, 
1165.78 cm
-1
; 
1
H NMR (acetone-d6, 400 MHz) δ 6.74 (br. s, 2 H), 6.46 (dd, 1 H, J = 18.0, 6.0 
Hz), 5.87 (d, 1 H, J = 8.4 Hz), 5.52 (dd, 1 H, J = 17.6, 1.0 Hz), 4.19 (app. br. s, 1 H), 1.69 (hept., 
1 H, J = 6.8 Hz), 1.45-1.29 (m, 11 H), 0.92 (d, 3 H, J = 6.4 Hz), 0.91 (d, 3 H, J = 6.8 Hz); 13C 
NMR (acetone-d6, 100 MHz) δ 156.1, 152.2, 122.8, 78.4, 52.9, 44.8, 28.7, 25.5, 23.2, 22.4; 
HRMS (HESI) m/z calcd for C8H17BNO4 (M-C4H8+H) 202.1245, found 202.1244. 
 
 
 
2-42 
N-[(2E)(4R)-5-Hydroxy-4-benzylpent-2-enyl](tert-butoxy)carboxamide (2-43).  To a 
solution of methyl boronic acid (0.030 g, 0.49 mmol), 2-34 (0.091 g, 0.45 mmol), 2-40 TFA salt 
(0.026 g, 0.072 mmol), and molecular sieves (4 Å beads, 0.230 g) in EtOAc (7 mL) was added 
hydrocinnamaldehyde (0.050 mL, 0.359 mmol) and copper acetate (0.014 g, 0.076 mmol). The 
headspace was purged with a gentle stream of O2 for 1 min and the reaction mixture was allowed 
to stir under an atmosphere of O2 (balloon) for 48 h at rt. The solution turned blue to green 
during this time. The reaction mixture was diluted with 10% EtOH in CH2Cl2 (10 mL), the 
solution was cooled to -78 
o
C, NaBH4 (0.101 g, 2.62 mmol) was added in one portion, and the 
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resulting mixture was allowed to stir for 30 min at the same temperature before warming to rt 
over 1 h. The reaction mixture was poured into half saturated NH4Cl (20 mL) at 0 
o
C and 
allowed to warm to rt over 30 min while stirring. The layers were separated and the aqueous 
phase extracted with CH2Cl2 (3 x 30 mL). The organic phases were dried (MgSO4), filtered, and 
the solvent evaporated under reduced pressure to give crude 2-42 (0.060 g) as a clear, colorless 
oil. The crude residue was purified by chromatography on SiO2 (50% Et2O in hexanes) to give 2-
42 (0.022 g, 0.076 mmol, 33%) as a clear, colorless oil: [α]D -14.6
 
(c 0.50, CHCl3); IR (CH2Cl2) 
3341.12, 2976.54, 2923.64, 1687.16 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 7.29-7.25 (m, 2 H), 
7.20-7.13 (m, 3 H), 5.48 (app d, 2 H, J = 4.0 Hz), 4.54 (br s, 1 H), 3.66 (app br s, 2 H), 3.59 (dd, 
1 H, J = 10.8, 4.8 Hz), 3.46 (dd, 1 H, J = 10.6, 7.6 Hz); 2.73 (dd, 1 H, J = 13.2, 6.8 Hz), 2.65-
2.59 (m, 1H), 2.56-2.51 (m, 1 H), 1.44 (s, 9 H); 
13
C NMR (CHCl3, 100 MHz) δ 155.9, 139.8, 
133.2, 129.5, 129.3, 128.4, 126.2, 79.6, 65.1, 46.9, 42.7, 37.7, 28.5; HRMS (HESI) m/z calcd for 
C17H25NO3 (M+Na) 314.1732, found 314.1724. 
 
 
2-43 
(E)-(3-((tert-Butoxycarbonyl)amino)prop-1-en-1-yl)trifluoroborate (2-43). A solution 
of 2-34 (3.21 g) in MeOH (21 mL) was treated dropwise via syringe with sat. aq. KHF2 (0.842 g, 
52.2 mmol) at rt over 5 min and the resulting solution was allowed to stir at rt for 2 h. The 
solvent was removed under reduced pressure and the residue dried under high vacuum overnight. 
Extraction of the solid residue with acetone (3 x 50 mL) followed by concentration under 
reduced pressure, addition of Et2O (100 mL) and filtration gave 2-43 (1.723 g, 6.549 mmol, 
63%) as a white, crystalline solid: Mp 129-131 
o
C (acetone/Et2O); IR (ATR) 3355.79, 2978.67, 
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2933.66, 1676.59, 1648.34, 1521.86 cm
-1
; 
1
H NMR (acetone-d6, 400 MHz) δ 5.68 (dt, 2 H, J = 
17.6, 5.2 Hz), 5.53-5.48 (m, 1 H), 3.56 (app. s, 2 H), 1.40 (s, 9 H); 
13
C NMR (acetone-d6, 100 
MHz) δ 156.6, 132.7, 78.2, 45.8, 28.7; HRMS (HESI) m/z calcd for C8H14O2NBF3 (M-K) 
224.1063, found 224.1064. 
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